



Revised Clinical Study Protocol

Study Code	D6930C00002 (PT007002)
NCT #	NCT03371459
Date	15 MARCH 2018
Version	4.0

**Albuterol Sulfate Pressurized Inhalation Suspension(PT007) Cumulative
Dose Study in Subjects With Mild to Moderate Asthma**

This submission /document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.

The following Amendment(s) are included in this revised protocol:

Amendment No.	Date of Amendment
Version 1	30 OCT 2017
Version 2, Amendment 1	10 NOV 2017
Version 3, Amendment 2	12 JAN 2018
Version 4, Amendment 3	15 MAR 2018

Revised Clinical Study Protocol

Drug Substance	PT007
Study Code	D6930C00002 (PT007002)
Version	4.0
Date	15 March 2018

Albuterol Sulfate Pressurized Inhalation Suspension (PT007) Cumulative Dose Study in Subjects With Mild to Moderate Asthma

Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden

VERSION HISTORY

Version 4.0, 15 March 2018
<p>The Per Protocol analysis set is defined and will serve as the primary analysis set for the extrapulmonary pharmacodynamic parameters. The originally planned Safety analysis set is anti-conservative in a non-inferiority/equivalence testing paradigm. Section 8.3 and the protocol have been updated accordingly.</p> <p>The specification of maximum change from baseline and time-weighted average change from baseline, both after the last cumulative dose, were added to the analyses of extrapulmonary PD parameters in Section 8.5.4.</p> <p>References to plasma concentrations of albuterol were inadvertently changed to serum concentrations throughout Version 3.0 of the protocol. Such references have been reverted back to plasma concentrations.</p>
Version 3.0, 12 January 2018
<p>Post-dose spirometry will be collected at 180 and 300 minutes, in addition to the timepoints currently outlined in the protocol. The 180 and 300 minute timepoints were inadvertently not included. Table 2 and the protocol have been updated accordingly.</p> <p>Figure 1 was corrected to state the follow up phone call period is 3 – 7 days vs. 5 – 7 days as written in Versions 1.0 and 2.0.</p> <p>Table 1 was updated to add the superscript “d” to spirometry. This footnote applies to spirometry as well as reversibility testing.</p> <p>Section 4.1.1 and 4.1.2, Visit 1 activities: clarifies that spirometry assessments should be performed only if subjects held their morning doses of asthma medications and SABA for ≥6 hours, per Table 1 and inclusion criteria 5. The previous text was confusing to sites.</p> <p>Section 4.2.2: moved “conducting pre-dose spirometry” from an after randomization activity to a before randomization activity. A pre-bronchodilator FEV₁ ≥40% percent predicted normal value is a randomization criterion.</p>
Version 2.0, 10 November 2017
<p>Glucose and potassium will be measured in serum instead of plasma. This is a global change throughout the protocol. Measuring glucose and potassium in serum vs. plasma is a more reasonable and practical approach.</p>

Clinical Study Protocol
Drug Substance PT007
Study Code D6930C00002 (PT007002)
Version 4.0
Date 15 March 2018

Version 1.0, 30 October 2017
Initial creation.

Clinical Study Protocol
Drug Substance PT007
Study Code D6930C00002 (PT007002)
Version 4.0
Date 15 March 2018

This clinical study protocol has been subject to a peer review according to the Sponsor's Standard procedures. The clinical study protocol is publicly registered and the results are disclosed and/or published according to the Sponsor's Global Policy on Bioethics and in compliance with prevailing laws and regulations.

CLINICAL STUDY PROTOCOL SYNOPSIS

Albuterol Sulfate Pressurized Inhalation Suspension (PT007) Cumulative Dose Study in Subjects With Mild to Moderate Asthma



Study sites and number of subjects planned

The study will be conducted at approximately 5 sites in the United States. Across these sites, it is planned that approximately 38 subjects will be randomized. Approximately 20 of these subjects will also participate in the pharmacokinetic (PK) substudy.

Phase of development
II

Study design

This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to assess the safety, efficacy, PK, and extrapulmonary pharmacodynamics (PD) of cumulative doses of Albuterol Sulfate Pressurized Inhalation Suspension (hereafter referred to as AS MDI) compared to cumulative doses of Proventil[®] hydrofluoroalkane (HFA; hereafter referred to as Proventil) as an active control in subjects with mild to moderate asthma.

Objectives

Primary Objective	Outcome Measures
To assess the efficacy of AS MDI compared to Proventil on lung function after cumulative doses of up to 1440 µg	<u>Primary</u> Baseline-adjusted forced expiratory volume in 1 second (FEV ₁) 30 minutes after each cumulative dose <u>Secondary</u> Baseline-adjusted FEV ₁ area under the curve from 0 to 6 hours (AUC ₀₋₆) after the last cumulative dose

Secondary Objective	Outcome Measures
To assess the extrapulmonary PD effects of AS MDI and Proventil after each cumulative dose up to a cumulative dose of 1440 µg	<p>The following variables will be collected at 15 minutes after each cumulative dose and 30, 60, 120, 180, 240, 300, and 360 minutes after the last cumulative dose:</p> <ul style="list-style-type: none"> • Fridericia-corrected QT interval (QTcF) and heart rate (HR) • Serum glucose and potassium • Diastolic blood pressure (DBP) and systolic blood pressure (SBP)

Safety Objective	Outcome Measure
To assess the safety of cumulative doses of AS MDI relative to Proventil	Adverse events (AEs)/serious adverse events (SAEs)

PK substudy	Outcome Measures
To compare the relative systemic bioavailability of albuterol delivered from AS MDI and Proventil after cumulative doses up to 1440 µg	<p>Plasma concentration observed at 15 minutes post each cumulative dose (C_{15min})</p> <p>AUC from time 0 to the time of the last measurable plasma concentration (AUC_{0-t}) post the final cumulative dose</p> <p>Maximum observed plasma concentration (C_{max}) and time to reach C_{max} (T_{max}) after the last dose</p>

Target subject population

Adult subjects (≥ 18 - ≤ 45 years old) with stable mild to moderate asthma (pre-bronchodilator FEV_1 of ≥ 50 to $< 80\%$ predicted normal value), with demonstrated FEV_1 reversibility to Ventolin[®] HFA (hereafter referred to as Ventolin).

Subjects must be on either a short-acting β -agonist (SABA) as needed as their only asthma therapy or a low to medium inhaled corticosteroid (ICS) dose (either alone or in combination with a long-acting β_2 -agonist [LABA]) for at least 30 days as a consistent regimen before screening.

Duration of treatment

This is a 2-period crossover study. Each Treatment Period will be 1 day, with a Washout Period of 3 to 7 days between Treatment Periods.

All subjects in this study will discontinue their current asthma medications at Visit 1 (Screening) and initiate Sponsor-provided asthma medication to be used during the Screening Period and throughout the duration of the study, as follows:

- Subjects who were using only SABA as needed before Visit 1 will discontinue their SABA and initiate Sponsor-provided Ventolin, to be used as needed until 48 hours before Visit 2. They will then discontinue Sponsor-provided Ventolin and initiate Sponsor-provided Atrovent for the duration of the study, to be used as needed up until 8 hours before each study visit.
- Subjects who were receiving regularly scheduled ICS or ICS/LABA before Visit 1 will discontinue their ICS or ICS/LABA and initiate Pulmicort Flexhaler 180 µg or 360 µg twice a day, in addition to the Sponsor-provided Ventolin and Atrovent to be used as described above.

Each subject will participate for a minimum of 13 days and up to a maximum of 44 days, including a 3- to 28-day Screening Period and a telephone call 3 to 7 days after the final dose of study drug. The Screening Period includes a minimum 14-day Run-in Period for subjects who were receiving regularly scheduled ICS or ICS/LABA before study entry and who will be switched to Pulmicort Flexhaler 180 µg or 360 µg twice a day.

Subjects enrolled in the PK substudy will have blood drawn at each Treatment Visit for albuterol concentrations.

Investigational product, dosage, and mode of administration

Test product: AS MDI; 90 µg albuterol base (which equals 108 µg albuterol sulfate) per actuation

Comparator: Proventil; 90 µg albuterol base (which equals 108 µg albuterol sulfate) per actuation

Each product is taken as 1+1+2+4+8 actuations (90, 90, 180, 360, and 720 µg, respectively), for a cumulative dose of 1440 µg during 1 of 2 Treatment Visits.

Statistical methods

All efficacy assessments will be compared with Proventil. The Modified Intent-to-Treat analysis set (defined as subjects who received treatment and have post-treatment efficacy data from both Treatment Periods) will be used for all efficacy assessments. The primary endpoint will also be evaluated using the Intent-to-Treat analysis set (defined as subjects who are randomized to treatment and receive at least 1 dose of the study treatment).

The primary endpoint, change from baseline in FEV₁ 30 minutes post each of the cumulative doses, will be analyzed using a linear mixed effect model with a random subject effect for the correlation across periods and an unstructured covariance matrix for the repeated measures

within subject periods. In the event that the unstructured matrix fails to converge, the heterogeneous Toeplitz structure will be fit. The fixed effects will include treatment, baseline FEV₁, and period. Ninety-percent confidence intervals (CIs) will be calculated for the between-treatment differences after each cumulative dose and will be evaluated for containment within the equivalence bounds of ± 200 mL.

The secondary efficacy endpoint, change from baseline in FEV₁ AUC₀₋₆, will be analyzed using a linear mixed model with a random subject effect. The fixed effects in the model will include treatment, baseline FEV₁, and period. A 90% CI for the between-treatment difference will be calculated and assessed for containment with the equivalence bounds of ± 200 mL.

Baseline FEV₁ will be defined as the mean of available pre-dose values on the first day of each Treatment Period (ie, the mean of pre-dose values at Visits 2 and 3, where the mean of the -60 and -30 minute values for each visit day is obtained and then the average of the 2 visit means is obtained).

Extrapulmonary PD parameters of QTcF, HR, serum glucose, serum potassium, SBP, and DBP will each be analyzed using a similar model as described above for FEV₁ parameters post each cumulative dose. Between-treatment differences and corresponding 90% CIs will be provided. The primary analyses of extrapulmonary PD parameters will be based on the Per Protocol analysis set. Supportive analyses of the extrapulmonary PD parameters will be based on the Safety analysis set.

The C_{15min} values for albuterol after each cumulative dose will be analyzed with a power law model.

Adverse events will be tabulated by treatment. No hypothesis tests will be performed.

PK substudy: Natural log-transformed AUC_{0-t} and C_{max} values for albuterol post the final cumulative dose will each be analyzed with a linear mixed effects model containing fixed effects for treatment and period. Subject will be included as a random effect. Estimated geometric mean ratios with 90% CIs will be provided.

Sample size

Randomization of 38 subjects to achieve 30 subjects completing the study will provide 90% probability to demonstrate equivalence within ± 200 mL after all 5 cumulative doses (intersection-union test). This calculation assumes a true treatment difference (AS MDI–Proventil) of 35 mL, intra-subject standard deviation of 174 mL, and two one-sided 5% level tests (TOST).

Enrollment of 20 subjects to obtain 14 subjects completing the PK substudy will provide 95% probability to observe a one-sided upper 95% confidence bound for the C_{max} ratio (AS MDI/Proventil) that is less than 1.50 even if the true ratio is as high as 1.15. This calculation assumes an intra-subject coefficient of variation of 22% for Proventil and a one-sided 5% test.

	PAGE
TITLE PAGE	1
VERSION HISTORY	2
CLINICAL STUDY PROTOCOL SYNOPSIS.....	5
TABLE OF CONTENTS.....	9
1. INTRODUCTION	16
1.1 Background and rationale for conducting this study	16
1.2 Rationale for study design, doses and control groups.....	16
1.3 Benefit/risk and ethical assessment.....	18
1.4 Study design.....	18
1.5 Study governance and oversight	22
2. STUDY OBJECTIVES.....	22
2.1 Primary objective	22
2.2 Secondary objectives	22
2.3 Safety objectives	22
2.4 PK substudy	23
2.5 Exploratory objectives – not applicable.....	23
3. SUBJECT SELECTION, ENROLLMENT, RANDOMIZATION, RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL	23
3.1 Inclusion criteria	23
3.2 Exclusion criteria	25
3.3 Subject enrollment and randomization	27
3.3.1 Randomization criteria.....	27
3.3.2 Subject identification	27
3.3.3 Screen failures.....	27
3.4 Procedures for handling incorrectly enrolled or randomized subjects.....	28
3.5 Methods for assigning treatment groups.....	28
3.6 Methods for ensuring blinding – not applicable	28
3.7 Methods for unblinding – not applicable	28
3.8 Restrictions	28
3.8.1 Illicit drugs	28
3.8.2 Dietary restrictions.....	29

3.9	Discontinuation of study drug.....	29
3.10	Discontinuation of the study	30
4.	STUDY PLAN AND TIMING OF PROCEDURES.....	30
4.1	Screening Period (Visits 1, and Visits 1a/1b if applicable)	34
4.1.1	Visit 1	34
4.1.2	Visit 1a	35
4.1.3	Visit 1b.....	35
4.2	Treatment periods	36
4.2.1	General guidance for Visits 2 and 3	36
4.2.2	Visit 2 (Randomization Visit, Treatment Period 1)	37
4.2.3	Visit 3 (Treatment Period 2)	39
4.2.4	Premature Study Withdrawal Visit	40
4.3	Follow-up period.....	41
4.3.1	Follow-up telephone call.....	41
4.3.2	Premature withdrawal from the study	41
5.	STUDY ASSESSMENTS	41
5.1	Efficacy assessments.....	41
5.1.1	Standardization of spirometry	42
5.1.2	Assessment of FEV ₁	42
5.1.3	Characterization of reversibility.....	43
5.1.4	FEV ₁ baseline stability criteria	43
5.2	Safety assessments	43
5.2.1	Medical/surgical history and physical examination.....	44
5.2.2	SBP and DBP	44
5.2.3	Clinical laboratory testing.....	44
5.2.4	ECG.....	45
5.3	Other assessments – not applicable.....	46
5.4	PK substudy	46
5.4.1	Collection of samples	46
5.4.2	Determination of drug concentration	46
5.4.3	Storage and destruction of PK samples.....	46
5.5	Pharmacodynamics	47
5.6	Genetics – not applicable	47
5.7	Biomarker analysis – not applicable	47
6.	SAFETY REPORTING AND MEDICAL MANAGEMENT	47
6.1	Definition of AEs	47
6.2	Definitions of SAE.....	48
6.3	Recording of AEs.....	49

6.3.1	Performing AE assessments.....	49
6.3.2	Pre-randomization AEs	49
6.3.3	AEs based on signs and symptoms	49
6.3.4	AEs based on examinations and tests	49
6.3.5	Disease under study	50
6.3.6	Severity	50
6.3.7	Relationship to study drug	50
6.4	Reporting of SAEs	51
6.4.1	Supplemental investigations of SAEs.....	51
6.4.2	Post-study follow-up of AEs.....	51
6.4.3	Notification of post-treatment SAEs.....	51
6.4.4	IRB notification of SAEs	52
6.4.5	Health Authority Safety Reports.....	52
6.5	Overdose	52
6.6	Pregnancy.....	52
6.6.1	Maternal exposure.....	52
6.6.2	Paternal exposure	53
6.7	Medication error.....	53
6.8	Management of study drug-related toxicities – not applicable	54
7.	INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS	54
7.1	Identity of investigational product(s).....	54
7.2	Dose and treatment regimens.....	55
7.2.1	Instructions for preparation of treatments for administration and dispensing	56
7.2.2	Randomized study drug	56
7.2.3	Sponsor-provided background asthma therapies	57
7.3	Labeling	58
7.3.1	Primary packaging and labeling.....	58
7.3.2	Secondary packaging and labeling information (box)	58
7.4	Storage	59
7.5	Compliance	59
7.6	Accountability.....	59
7.7	Concomitant and other treatments	60
7.7.1	Prior medications	60
7.7.2	Concomitant medications.....	61
7.7.2.1	Required concomitant medications.....	61
7.7.2.2	Allowed allergy medications	62
7.7.3	Prohibited medications.....	62
7.7.3.1	Prohibited asthma and allergy medications and washout periods.....	62
7.7.3.2	Prohibited non-asthma and non-respiratory medications	63
7.7.4	Other concomitant treatment.....	64

8.	STATISTICAL ANALYSES	65
8.1	Statistical considerations.....	65
8.2	Sample size estimate	65
8.3	Definitions of analysis sets	65
8.4	Outcome measures for analyses	66
8.5	Methods for statistical analyses	66
8.5.1	Primary efficacy analysis	66
8.5.2	Secondary efficacy analysis	67
8.5.3	Data validation and transformation.....	67
8.5.4	Extrapulmonary PD analysis.....	67
8.5.5	PK substudy: PK analysis	68
8.5.5.1	PK parameters	68
8.5.5.2	Handling of values below the limit of quantification	68
8.5.5.3	Statistical analysis of PK data.....	68
8.5.6	Safety analyses	69
8.5.7	Handling of missing data	69
8.5.8	Statistical software	69
9.	STUDY AND DATA MANAGEMENT BY THE SPONSOR	69
9.1	Training of study site staff	69
9.2	Monitoring of the study	70
9.2.1	Study agreements	70
9.2.2	Archiving of study documents	70
9.3	Study timetable and end of study	70
9.4	Data management.....	71
10.	ETHICAL AND REGULATORY REQUIREMENTS	71
10.1	Ethical conduct of the study	71
10.2	Subject data protection.....	71
10.3	Ethics and regulatory review.....	71
10.4	Informed consent	72
10.5	Changes to the clinical study protocol and ICF	72
10.6	Audits and inspections	73
11.	LIST OF REFERENCES	74

LIST OF TABLES

Table 1	Schedule of Events	31
---------	--------------------------	----

Table 2	Timed Assessments at Each Treatment Visit (Visit 2 and Visit 3)	33
Table 3.	List of Laboratory Tests to be Performed at Screening.....	45
Table 4.	Randomized Study Drugs	55
Table 5.	Other Sponsor-provided Study Medications	55
Table 6	Dose of Sponsor-provided Pulmicort Flexhaler to be Assigned Based on Pre-study ICS or ICS/LABA Dose	61
Table 7	Allowed Allergy Medications	62
Table 8	Prohibited Asthma and Allergy Medications That Must be Discontinued at Visit 1 and Required Washout Period Prior to the Next Visit.....	63
Table 9	Prohibited Non-Asthma and Non-Respiratory Medications	64
Table A1-1.	Recommended Minimal Scale Factors for Time, Volume and Flow on Graphical Output	78
Table A1-2.	Summary of Equipment Quality Control	79
Table A1-3.	Range and Accuracy Recommendations Specified for Forced Expiratory Maneuvers	81

LIST OF FIGURES

Figure 1	Study Design Flow Chart	21
----------	-------------------------------	----

LIST OF APPENDICES

Appendix A	Spirometry Assessment Criteria	75
Appendix B	Spirometry Performance Recommendations	77
Appendix C	Additional Safety Information.....	83
Appendix D	Instructions for Use of Inhaled Medications	85
Appendix E	Sponsor Signatory	99
Appendix F	Investigator's Agreement and Signature Page.....	100

LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

The following abbreviations and special terms are used in this study clinical study protocol.

Abbreviation or special term	Explanation
AE	Adverse event
AS MDI	Albuterol Sulfate Pressurized Inhalation Suspension
ATS	American Thoracic Society
AUC	Area under the curve
AUC ₀₋₆	Area under the curve from 0 to 6 hours
AUC _{0-t}	Area under the curve from 0 to the time of the last measurable plasma concentration
β-hCG	β-human chorionic gonadotropin
BID	Twice a day
C _{15min}	Plasma concentration observed at 15 minutes post each cumulative dose
CFR	Code of Federal Regulations
CI	Confidence interval
C _{max}	Maximum observed plasma concentration
CSR	Clinical study report
DBP	Diastolic blood pressure
ECG	Electrocardiogram
eCRF	Case Report Form (electronic/paper)
ERS	European Respiratory Society
FEV ₁	Forced expiratory volume in 1 second
GCP	Good Clinical Practice
HFA	Hydrofluoroalkane
HR	Heart rate
ICF	Informed consent form
ICH	International Conference for Harmonisation
ICS	Inhaled corticosteroid
ID	Identification
IRB	Institutional Review Board
ITT	Intent-to-treat

Abbreviation or special term	Explanation
IWRS	Interactive Web Response System
LABA	Long-acting β 2-agonist
LLQ	Lower limit of quantitation
MDI	Metered dose inhaler
MedDRA	Medical Dictionary for Regulatory Activities
mITT	Modified ITT
NCA	Noncompartmental analysis
PD	Pharmacodynamic
PIN	Personal ID number
PK	Pharmacokinetic
PFT	Pulmonary function testing
QTc	Corrected QT interval
QTcF	Fridericia-corrected QT interval
SABA	Short-acting β -agonist
SAE	Serious adverse event
SAP	Statistical Analysis Plan
SBP	Systolic blood pressure
TOST	Two one-sided tests
T _{max}	Time to reach C _{max}

1. INTRODUCTION

1.1 Background and rationale for conducting this study

Asthma is a heterogeneous disease that is characterized by chronic airway inflammation and bronchial hyperreactivity. It is defined by a history of respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow obstruction. Worsening asthma symptoms/airway obstruction can be mild to severe ([Global Initiative for Asthma 2017](#)). Albuterol sulfate is a short-acting β -agonist (SABA) that has been used world-wide in the management of asthma symptoms across all severities of asthma for over 40 years ([Global Initiative for Asthma 2017](#)).

The test formulation to be evaluated in this study is a metered dose inhaler (MDI) containing albuterol sulfate (Albuterol Sulfate Pressurized Inhalation Suspension; hereafter referred to as AS MDI). This is a cumulative dose study designed to assess the efficacy of AS MDI compared to Proventil[®] hydrofluoroalkane (HFA; hereafter referred to as Proventil) on lung function after cumulative doses of up to 1440 μ g. The pharmacokinetics (PK) and relative systemic bioavailability of AS MDI will be compared with Proventil. The study will also assess extrapulmonary pharmacodynamics (PD) as well as the safety and tolerability of AS MDI following cumulative doses in adult subjects with mild to moderate asthma.

The drug product in clinical development is an MDI formulated as a suspension with a micronized active pharmaceutical ingredient and Co-Suspension[™] Delivery Technology, which consists of spray-dried porous particles comprised of the phospholipid, 1,2-distearoyl-sn-glycero-3-phosphocholine and calcium chloride suspended in a HFA propellant. When used in MDI products, these particles form strong non-specific associations with the active pharmaceutical ingredient, providing reproducible drug delivery and long-term stability.

All references to doses of AS MDI and Proventil refer to the albuterol base (ie, 90 μ g albuterol base, which equals 108 μ g albuterol sulfate).

1.2 Rationale for study design, doses and control groups

The primary goal of this study is to assess the safety and efficacy of cumulative doses of AS MDI compared to cumulative doses of Proventil in subjects with mild to moderate asthma. The study is based on a 2-period crossover design to allow the comparison of AS MDI against the active comparator, Proventil. The crossover design was selected to ensure acceptable power with limited subject exposure through within-subject treatment comparisons; this design has been used in other studies comparing inhaled albuterol treatments ([Kerwin et al 2016](#); [Tripp et al 2008](#)).

The dose levels of AS MDI and Proventil to be tested (5 cumulative doses administered 30 minutes apart as 1+1+2+4+8 inhalations of 90 μ g albuterol for a total albuterol dose of 1440 μ g) will allow evaluation of the bronchodilation effect of AS MDI relative to the reference product and will also allow for a comparison of the extrapulmonary PD of the 2 products. The efficacy, safety, and extrapulmonary PD effects of inhaled albuterol following

this dosing regimen have been well documented in previous albuterol cumulative dose studies (Kerwin et al 2016; Tripp et al 2008).

This is an open-label study and study subjects are not blinded. However, to reduce bias, dosing will be performed under the supervision of study staff, and spirometry assessments will be performed by different study personnel who will only enter the room after dosing is completed; thus, the study personnel conducting the spirometry assessments will be blinded to the identity of the study drug.

Subjects enrolled in this study are selected to represent the intended patient population for an albuterol product to be used as needed for symptoms, ie, adults with mild to moderate asthma currently treated and well controlled with appropriate background standard of care for their asthma severity.

Subjects who were previously on a low to medium dose of an inhaled corticosteroid (ICS), with or without a long-acting β 2-agonist (LABA) before study entry, will be required to discontinue their previous therapy and initiate Sponsor-supplied Pulmicort Flexhaler™ for at least 14 days to standardize therapy and to confirm asthma is adequately treated prior to randomization.

All subjects will use only Sponsor-provided medication for rescue as needed during the study. At Visit 1 (Screening), subjects will discontinue their SABA and initiate Sponsor-provided Ventolin, to be used as needed until 48 hours before Visit 2. They will then discontinue Sponsor-provided Ventolin and initiate Sponsor-provided Atrovent® HFA (hereafter referred to as Atrovent) for the duration of the study, to be used as needed up until 8 hours before each study visit.

AS MDI will be compared with Proventil on the primary efficacy endpoint, baseline-adjusted forced expiratory volume in 1 second (FEV₁) 30 minutes after each cumulative dose. As a secondary efficacy endpoint, baseline-adjusted FEV₁ area under the curve (AUC) from 0 to 6 hours (AUC₀₋₆), a commonly accepted endpoint for the assessment of bronchodilation, will be determined after the last cumulative dose.

To characterize the PK of albuterol, approximately 20 subjects will be enrolled in a PK substudy. Pharmacokinetic parameters will be assessed for AS MDI relative to Proventil 15 minutes after each cumulative dose and through 12 hours after the last cumulative dose. The length of the Washout Period (3 to 7 days) has been set to make sure that carry-over effects are negligible with regard to PK and PD on the subsequent Treatment Period. The apparent terminal plasma half-life of albuterol is approximately 3 - 8 hours (Ahrens 1984).

It is well known that β -adrenergic agonists can produce cardiovascular effects, hypokalemia and hyperglycemia, due to their pharmacological effects (PROVENTIL HFA package insert; Philipson 2002). Therefore, this study will evaluate the short-term exposure-response relationships of extrapulmonary PD endpoints. The extrapulmonary PD of AS MDI and Proventil will be assessed throughout the dosing period through 6 hours after the last dose by

analysis of changes from baseline (pre-dose) in serum potassium and glucose, blood pressure, and electrocardiograms (ECGs).

1.3 Benefit/risk and ethical assessment

This study has been designed to support the dose selection for a new formulation of albuterol in subjects with mild to moderate asthma. The product being tested in this study, AS MDI, is being compared with an approved inhaled albuterol product to confirm a pharmacologically appropriate dose. The subjects in this study will not gain any therapeutic benefit from the study as it is comprised of only 2 single treatment days with high doses of albuterol.

All subjects in this study will be switched at Visit 1 from their current asthma medication to Sponsor-provided asthma medication to be used during the Screening Period and throughout the duration of the study, as described in Section 1.2. Subjects requiring medications other than those specified in Section 1.2 to control or treat their asthma symptoms before the first Screening Visit will be excluded from participation in this study. In addition, to be eligible for randomization, subjects must not have used more than 8 actuations per day (ie, 4 doses of 2 actuations per day) of Sponsor-provided rescue medication on more than any 3 days during the previous 7 days before randomization.

The doses of albuterol administered as AS MDI and Proventil to be tested in this study (5 cumulative doses administered 30 minutes apart as 1+1+2+4+8 inhalations of 90 µg albuterol for a total albuterol dose of 1440 µg) have been used in previous studies of inhaled albuterol (Kerwin et al 2016; Tripp et al 2008). Although a higher incidence of adverse events (AEs) was reported at supratherapeutic doses in these studies, the overall incidence of AEs was low. The most frequently reported treatment-emergent AEs following cumulative doses of inhaled albuterol were tremor (17.4%), headache (8.7%), and palpitations (8.7%), with the majority of events reported at the cumulative doses of 720 and 1440 µg (Kerwin et al 2016).

Laboratory parameters (serum glucose and potassium) and cardiovascular parameters (Fridericia-corrected QT interval [QTcF] and heart rate [HR]) will be monitored to assess the expected PD effects consistent with the mechanism of action of inhaled albuterol at the suprapharmacologic doses used in this study. The expected changes in these parameters were demonstrated at cumulative doses of albuterol up to 1440 µg, but mean changes in serum glucose level, serum potassium level, corrected QT interval (QTc), blood pressure, and HR were considered not clinically significant (Kerwin et al 2016). Investigators will ensure adequate medical care of the study participants at all times throughout the course of the study, including up to the follow-up telephone call 3 to 7 days after the last dose of study drug.

1.4 Study design

This is a randomized, cumulative dose, open-label, 2-period crossover, multi-center study to assess the safety, efficacy, PK, and extrapulmonary PD of cumulative doses of AS MDI compared to cumulative doses of Proventil as an active control in subjects with mild to moderate asthma (Figure 1).

This study will be conducted at approximately 5 sites in the US, contributing approximately 8 subjects per site. Across these sites, it is planned that approximately 38 subjects with mild to moderate asthma will be randomized to provide approximately 30 subjects to complete the study. Each subject will participate for a minimum of 13 days and up to a maximum of 44 days, including a 3- to 28-day Screening Period and a telephone call 3 to 7 days after the final dose of study drug. The study is anticipated to run for approximately 5 months, including the recruitment period.

This study consists of a Screening Period, which includes a Run-in Period for those subjects who will be switched from ICS to Sponsor-provided Pulmicort Flexhaler, a Treatment Phase, which includes 2 randomized Treatment Periods, and a follow-up telephone call. Each Treatment Period will be 1 day, with a Washout Period of 3 to 7 days between Treatment Periods.

The Screening Period begins at Visit 1. At Visit 1, subjects will sign an informed consent form (ICF), and inclusion/exclusion criteria will be assessed. To be eligible, subjects must be on either a SABA as needed as their only asthma therapy or a low to medium ICS dose (either alone or in combination with a LABA) for at least 30 days as a consistent regimen before screening. Subjects must have a pre-bronchodilator FEV₁ between ≥ 50 and $< 80\%$ predicted normal value.

All subjects must demonstrate FEV₁ reversibility to Ventolin (defined as improvement in FEV₁ of $\geq 15\%$ post Ventolin dosing) during the Screening Period; historical reversibility is not acceptable. For subjects who did not administer their morning asthma maintenance medications and/or SABA, reversibility will be measured at Visit 1. For subjects who received their morning asthma maintenance medications and/or SABA, reversibility will be measured at Visit 1a, which will occur within 10 days of Visit 1 and after these medications have been held for the appropriate time period (Table 8). Subjects who do not meet reversibility criteria at Visit 1 or Visit 1a may be retested at a subsequent Screening Visit (1a or 1b). Only 2 reversibility testing attempts are allowed. Subjects not meeting reversibility criteria after 2 attempts must be screen failed.

Subjects meeting eligibility criteria at Visit 1 will enter a Screening Period. All subjects in this study will discontinue their current asthma medications at Visit 1 and initiate Sponsor-provided asthma medication to be used during the Screening Period and throughout the duration of the study, as follows:

- Subjects who were using only SABA as needed before Visit 1 will discontinue their SABA and initiate Sponsor-provided Ventolin, to be used as needed until 48 hours before Visit 2. They will then discontinue Sponsor-provided Ventolin and initiate Sponsor-provided Atrovent for the duration of the study, to be used as needed up until 8 hours before each study visit.
- Subjects who were receiving regularly scheduled ICS or ICS/LABA before Visit 1 will discontinue their ICS or ICS/LABA and initiate

Pulmicort Flexhaler 180 µg or 360 µg twice a day (BID) (see [Table 6](#)), in addition to the Sponsor-provided Ventolin and Atrovent to be used as described above.

For subjects who were using only SABA as needed for rescue before study entry, the minimum Screening Period will be 3 days. For subjects who were receiving regularly scheduled ICS or ICS/LABA before study entry and who switch to Pulmicort Flexhaler, the minimum Run-in Period will be 14 days. For all subjects, the maximum Screening/Run-in Period will be 28 days. Subjects will use only these Sponsor-provided asthma medications throughout the Screening/Run-in Period and for the remainder of the study during both the Treatment Periods and Washout Period.

Randomization will take place at Visit 2. At Visit 2, before randomization, subjects must demonstrate a pre-bronchodilator $FEV_1 \geq 50\%$ predicted normal value (average of 2 pre-bronchodilator assessments). Subjects who do not meet this randomization criterion will be screen failed. Randomization will be centralized through the use of an Interactive Web Response System (IWRS). Subjects will be randomized to 1 of 2 treatment sequences, A/B or B/A, where:

- A=AS MDI 1+1+2+4+8 inhalations of 90 µg per inhalation
- B=Proventil 1+1+2+4+8 inhalations of 90 µg per inhalation

At each Treatment Visit (Visits 2 and 3), subjects will receive 5 doses of open-label study drug (AS MDI or Proventil), 30 minutes apart. A 3- to 7-day Washout Period will occur between Treatment Visits. At each Treatment Visit, bronchodilation activity of the study drug will be assessed through pulmonary function testing (PFT), and extrapulmonary PD variables will be assessed (serum potassium and glucose, diastolic blood pressure [DBP], systolic blood pressure [SBP], QTcF, and HR).

Subjects will be required to remain at the clinic until completion of all protocol-defined assessments ([Table 1](#)). Safety will also be assessed by evaluation of AEs.


Subjects who prematurely discontinue study drug for any reason before completing all study visits will undergo a Premature Discontinuation Visit. After the second Treatment Visit or following the Premature Discontinuation Visit, subjects will be scheduled for a follow-up telephone call 3 to 7 days from the date of the last study drug dose.

The end of study is defined as the last subject's follow-up telephone call.

PK substudy

Approximately 20 subjects will also participate in a PK substudy. Pharmacokinetic samples will be collected 15 minutes after each cumulative dose and through 12 hours after the last dose of study drug (see [Table 2](#)).

Figure 1 Study Design Flow Chart



*Subjects on ICS or ICS/LABA prior to Visit 1 will be run-in on Pulmicort Flexhaler 180 or 360 µg BID for a minimum of 14 days.

Abbreviations: V=visit; R=randomization.

1.5 Study governance and oversight

No study governance or oversight committees will be used in this study.

2. STUDY OBJECTIVES

2.1 Primary objective

Primary Objective	Outcome Measure
To assess the efficacy of AS MDI compared to Proventil on lung function after cumulative doses of up to 1440 µg	<u>Primary</u> Baseline-adjusted FEV ₁ 30 minutes after each cumulative dose <u>Secondary</u> Baseline-adjusted FEV ₁ AUC ₀₋₆ after the last cumulative dose

2.2 Secondary objectives

Secondary Objectives	Outcome Measure
To assess the extrapulmonary PD effects of AS MDI and Proventil after each cumulative dose up to a cumulative dose of 1440 µg	The following variables will be collected at 15 minutes after each cumulative dose and 30, 60, 120, 180, 240, 300, and 360 minutes after the last cumulative dose: <ul style="list-style-type: none"> • QTcF and HR • Serum glucose and potassium • DBP and SBP

2.3 Safety objectives

Safety Objective	Outcome Measure
To assess the safety of cumulative doses of AS MDI relative to Proventil	AEs/serious adverse events (SAEs)

2.4 PK substudy

PK Objective	Outcome Measure
To compare the relative systemic bioavailability of AS MDI and Proventil after cumulative doses up to 1440 µg	Plasma concentration observed at 15 minutes post each cumulative dose (C_{15min}) AUC from time 0 to the time of the last measurable plasma concentration (AUC_{0-t}) post the final cumulative dose Maximum observed plasma concentration (C_{max}) and time to reach C_{max} (T_{max}) after the last dose

2.5 Exploratory objectives – not applicable

3. SUBJECT SELECTION, ENROLLMENT, RANDOMIZATION, RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL

Each subject must meet all of the inclusion criteria and none of the exclusion criteria for this study. Under no circumstances will there be exceptions to this rule.

3.1 Inclusion criteria

Each subject must meet the following criteria in relationship to Visit 1, unless otherwise noted, to be enrolled in this study:

1. Give their signed written informed consent to participate
2. Are at least 18 years of age and no older than 45 years
3. Have stable (for 6 months) physician-diagnosed asthma with historical documentation of the diagnosis
4. Must be receiving 1 of the following required inhaled asthma therapies listed below for at least the last 30 days:
 - Only SABA, which is used as needed for rescue
 - Low to medium doses of ICS (alone or in combination with LABA), used regularly as maintenance asthma therapy, with the ICS doses allowed in [Table 6](#), with a stable regimen
5. Pre-bronchodilator FEV₁ of ≥ 50 to $< 80\%$ predicted normal value after withholding SABA ≥ 6 hours (and/or at Visit 1a and/or 1b, if applicable)

6. Confirmed FEV₁ reversibility to Ventolin, defined as a post-Ventolin increase in FEV₁ of $\geq 15\%$ at either Visit 1, Visit 1a, or Visit 1b; only 2 reversibility testing attempts are allowed
7. Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society [ATS]/European Respiratory Society [ERS] acceptability/repeatability criteria; [Appendix A](#))
8. Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol
9. Demonstrate acceptable MDI administration technique.
Note: Use of a spacer device during the Screening and randomized Treatment Periods is not permitted.
10. Body mass index $< 40 \text{ kg/m}^2$
11. If a female of childbearing potential, have a negative serum pregnancy test
12. Women of childbearing potential must agree to 1 of the following to prevent pregnancy:
(Note: Women are considered to be of non-childbearing potential if they are physiologically incapable of becoming pregnant, including any female who is 2 years post-menopausal, or surgically sterile, defined as having a bilateral oophorectomy, hysterectomy, or tubal ligation). For purposes of this protocol, menopausal women are defined as women ≥ 50 years old who are amenorrheic for 12 consecutive months or more following cessation of all exogenous hormonal treatment)
 - Practice abstinence
 - If a female of childbearing potential and sexually active, agrees to prevent pregnancy by using 1 of the following methods of birth control from the date the ICF is signed until 2 weeks after the final dose of study drug is taken:
 - Hormonal contraception (eg, oral contraceptive, contraceptive implant, or injectable hormonal contraceptive)
 - Double-barrier birth control (eg, condom plus intrauterine device, diaphragm plus spermicide, or condom plus spermicide)
 - Maintenance of a monogamous sexual relationship with a male partner who has been surgically sterilized by vasectomy

13. Male subjects who are sexually active must be surgically sterile or agree to use a double-barrier method of contraception (condom with spermicide) from the first dose of randomized study drug until 2 weeks after their last dose, and must not donate sperm during their study participation period
14. Compliance: must be willing to remain at the study center as required per protocol to complete all visit assessments

3.2 Exclusion criteria

Subjects who meet any of the following criteria in relationship to Visit 1, unless otherwise stated, will be excluded from the study.

1. Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)
2. Oral corticosteroid use (any dose) within 6 weeks
3. Received any marketed (eg, omalizumab, mepolizumab, reslizumab) or investigational biologic within 3 months or 5 half-lives, whichever is longer, or any other medication specifically prohibited by the protocol within the indicated exclusionary time periods ([Table 8](#) and [Table 9](#))
4. Received tiotropium within 2 weeks
5. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana)
6. Life-threatening asthma as defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s)
7. Completed treatment for lower respiratory infection or asthma exacerbation within 6 weeks
8. Upper respiratory infection not resolved within 7 days
9. Hospitalizations for asthma within 6 months
10. Clinically significant laboratory abnormalities or ECG abnormalities, in the opinion of the Investigator
Note: if laboratory tests have to be repeated, the results should be available for review before Visit 2 (Randomization)

11. Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular (eg, congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia, coronary heart disease), hepatic, renal, hematological, neuropsychological, endocrine (eg, uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), or gastrointestinal (eg, poorly controlled peptic ulcer, gastroesophageal reflux disease). Significant is defined as any disease that, in the opinion of the Investigator, would put the safety of the subject at risk through study participation, or that could affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
12. Cancer not in complete remission for at least 5 years
Note: Subjects with squamous cell carcinoma of the skin, basal cell carcinoma of the skin, in situ carcinoma of the cervix, or localized prostate cancer are eligible, if in the opinion of the Investigator, the condition has been adequately worked up and clinically controlled and the subject's participation in the study would not represent a safety concern.
13. Hospitalized for psychiatric disorder or attempted suicide within 1 year
14. History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions limiting informed consent validity
15. Significant, in the opinion of the Investigator, abuse of alcohol or drugs
16. Hypersensitivity to β 2-agonists or any component of the investigational MDI or any component of Proventil, Ventolin, or Atrovent (or Pulmicort Flexhaler, if applicable)
17. Unable to abstain from protocol-defined prohibited medications during the study
18. Using any herbal products by inhalation or nebulizer within 2 weeks and does not agree to stop during the study duration
19. Received a live attenuated vaccination within 7 days
20. Currently pregnant or nursing
21. Study investigators, sub-investigators, coordinators, and their employees or immediate family members, or employees of the Sponsor
22. Treatment with investigational study drug (or device) in another clinical study within the last 30 days or 5 half-lives, whichever is longer
23. Randomized in any PT007 study

3.3 Subject enrollment and randomization

3.3.1 Randomization criteria

Each subject must meet the following criteria on the morning of Visit 2 to be randomized:

1. Subjects of childbearing potential must have a negative urine pregnancy test
2. Received no asthma medication other than Sponsor-provided Pulmicort Flexhaler 180 µg or 360 µg BID as assigned and/or Sponsor-provided Ventolin and Atrovent from Visit 1 to Visit 2, except for allowable allergy medications defined in [Table 7](#)
3. The last dose of Pulmicort Flexhaler (if applicable) was the previous night (ie, morning dose of Pulmicort Flexhaler was not administered), the last dose of Sponsor-provided Ventolin was no later than 48 hours before the study visit, and the last dose of Atrovent was no later than 8 hours before the study visit (if SABA is needed in the morning, the visit must be rescheduled)
4. Pre-bronchodilator FEV₁ ≥50% percent predicted normal value
5. Has not used >8 actuations per day (ie, 4 doses of 2 actuations per day) of Sponsor-provided rescue medication (Ventolin and Atrovent) for rescue on more than any 3 days during the previous 7 days
6. No upper respiratory infection, lower respiratory infection, or asthma exacerbation during the Screening Period
7. Demonstrate acceptable MDI administration technique
8. Able to comply with study procedures

For procedures for withdrawal of incorrectly randomized subjects see Section [3.4](#).

3.3.2 Subject identification

All subjects who undergo screening will be assigned a unique screening identification number (ID) at Visit 1. Only subjects continuing to meet all the inclusion criteria and none of the exclusion criteria at Visit 2 and who meet randomization criteria at Visit 2 will be assigned a unique subject randomization number.

3.3.3 Screen failures

Screening failures are subjects who do not fulfil the eligibility criteria for the study and therefore must not be randomized.

3.4 Procedures for handling incorrectly enrolled or randomized subjects

Subjects who fail to meet the eligibility criteria should not, under any circumstances, be enrolled into the Screening Period or receive study drug. There can be no exceptions to this rule. Subjects who are enrolled into the Screening Period but subsequently found not to meet all the eligibility criteria must not be randomized or initiated on study drug.

If a subject does not meet all the eligibility criteria and is randomized in error or is incorrectly started on study drug, the Investigator should inform the Sponsor immediately, and the Sponsor and the Investigator should discuss whether to continue or discontinue the subject from study drug and withdraw the subject from the study. The Sponsor must ensure all decisions are appropriately documented.

3.5 Methods for assigning treatment groups

The randomization scheme will be generated by the Sponsor or designee using computer software incorporating a random number generator. Subjects will be randomly assigned to 1 of 2 treatment sequences, A/B or B/A, using an IWRS. Each sequence will comprise the following cumulative dose treatment arms:

- A=AS MDI 1+1+2+4+8 inhalations of 90 µg per inhalation
- B=Proventil 1+1+2+4+8 inhalations of 90 µg per inhalation

Randomization will be centralized.

3.6 Methods for ensuring blinding – not applicable

3.7 Methods for unblinding – not applicable

3.8 Restrictions

Prohibited concomitant medications are described in Section [7.7.3](#).

3.8.1 Illicit drugs

Illicit drugs or drugs of abuse will not be allowed from Visit 1 to the end of the follow-up telephone call or to whenever the subject discontinues from the study drug and withdraws from the study. If any illicit drugs or drugs of abuse are used by the subject during the study, the dates of use and the amount will be documented and the subject will be discontinued from study drug and withdrawn from the study at the discretion of the Investigator. Medical marijuana (edibles and tinctures only; inhaled marijuana is excluded) is not an exclusionary drug if used for medical purposes and the dose or frequency of consumption does not change during the Screening Period or throughout the study.

3.8.2 Dietary restrictions


Subjects must not ingest xanthine and/or xanthine analogue (caffeine)-containing foods or beverages or caffeine-containing medications for at least 6 hours before each study visit and throughout the duration of each study visit. Examples of such products include coffee, tea, chocolate, and cola. Decaffeinated beverages are acceptable.

3.9 Discontinuation of study drug

All subjects who discontinue study drug will be withdrawn from the study.

Subjects may be withdrawn from the study at their own request at any time for any reason.

Subjects experiencing any of the changes of concern listed below should be discontinued from randomized study drug and withdrawn from the study.

- Asthma worsening requiring change in asthma treatment, other than Pulmicort Flexhaler, if assigned, and as needed Sponsor-provided Ventolin and Atrovent
Note: Subjects experiencing an asthma exacerbation during the study will be evaluated by the Investigator and treated with medications for asthma deemed medically necessary and will be discontinued from study drug and withdrawn from the study.
- 
- Requirement for any of the prohibited medications listed in Section [7.7.3](#)
- Any safety reason as judged by the Investigator and/or Sponsor
- Pregnancy
- The subject's treatment code is prematurely broken by the Investigator.

Subjects who discontinue study drug and withdraw from the study should be encouraged to complete the Premature Discontinuation Visit (see Section [4.2.4](#)).

Withdrawal of the informed consent

Subjects are free to withdraw from the study at any time without prejudice to further treatment.

A subject who withdraws consent will always be asked about the reason(s) and the presence of any AE. The Investigator will follow up AEs outside of the clinical study.

If a subject withdraws from participation in the study, then his/her enrollment and/or randomization code(s) cannot be reused. Withdrawn subjects will not be replaced.

3.10 Discontinuation of the study

The study may be stopped if, in the judgment of the Sponsor, study subjects are placed at undue risk because of clinically significant findings that:

- meet individual stopping criteria or are otherwise considered significant
- are assessed as causally related to study drug
- are not considered to be consistent with continuation of the study

The Sponsor reserves the right to terminate the study at any time for clinical or administrative reasons. Such a termination must be implemented by the Investigator, if instructed to do so by the Sponsor, in a time frame that is compatible with the subjects' well-being.

Regardless of the reason for termination, all data available for the subject at the time of discontinuation of follow-up must be recorded in the electronic case report form (eCRF). All reasons for discontinuation of study drug must be documented.

In terminating the study, the Sponsor will ensure that adequate consideration is given to the protection of the subjects' interests.

4. STUDY PLAN AND TIMING OF PROCEDURES

Note: Before conducting any study-related procedures, subjects are required to provide their written informed consent using the Institutional Review Board (IRB)-approved ICF. The ICF should be signed by the subject during Visit 1.

All study visits will take place at approximately the same time of day. A time and events schedule is provided in [Table 1](#). A detailed schedule of timed assessments is provided in [Table 2](#).

When post-dose data collection timepoints are concurrent, variables will be collected in the following order: blood pressure, ECG, clinical laboratory assessments, PK blood samples (if applicable), and spirometry.

Table 1 **Schedule of Events**

Procedures	Screening ^a		Treatment Phase		Follow-up	
	Visit 1	Visit 1a/1b	Randomization (TP 1) Day 1	Visit 3 ^b (TP 2)	PDV (if applicable) ^c	TC 3-7 days after final dose
		Day -28 to Day -1				
Informed consent	X					Section 10.4
Eligibility criteria	X					Section 3
Verify randomization criteria			X			Section 3.3.1
Verify continued eligibility		X		X		Section 3
MDI demonstration/training	X		X	X		Section 4.1
Ventolin reversibility test ^d	X	X				Section 5.1.3
Medical/surgical history	X					Section 5.2.1
Demographics	X					Section 4.1
Concomitant medications ^e	X	X	X	X	X	Section 7.7
Spirometry ^d	X	X	X	X		Section 5.1.2
				X		Section 5.1.4
Physical examination ^f	X			X	X	Section 5.2.1
SBP/DBP	X		X	X	X	Section 5.2.2
12-lead ECG	X		X	X	X	Section 5.2.4
Pregnancy test ^g	X		X			Section 5.2.3
Clinical laboratory testing	X					Section 5.2.3
PD sample collection			X	X	X	Section 5.2.3
Adjust asthma medications per protocol ^h	X			X	X	Section 7.7.2

Table 1 Schedule of Events

Procedures	Screening ^a		Treatment Phase		Follow-up	
	Visit 1	Visit 1a/1b	Randomization (TP 1) Day 1	Visit 3 ^b (TP 2)	PDV (if applicable) ^c	TC 3-7 days after final dose
		Day -28 to Day -1				
Randomization			X			Section 3.5
Randomized study drug administered			X	X		Section 7.2
PK sample collection ⁱ			X	X		Section 5.4.1
AEs	X	X	X	X	X	Section 6.3
Telephone contact					X	Section 4.3.1

Abbreviations: AE=adverse event; DBP=diastolic blood pressure; ECG=electrocardiogram; FEV₁=forced expiratory volume in 1 second; MDI=metered dose inhaler; PDV=Premature Discontinuation Visit; PK=pharmacokinetic; SABA= short-acting β -agonist; SBP=systolic blood pressure; TC=telephone call; TP=Treatment Period.

Note: When post-dose data collection timepoints are concurrent, variables will be collected in the following order: blood pressure, ECG, clinical laboratory assessments, PK blood samples (if applicable), and spirometry.

^a Screening Period will be 3 to 28 days for subjects on SABA only before study entry, and 14 to 28 days for subjects on ICS or ICS/LABA before study entry.

^b Subjects to return to clinic within 3 to 7 days following Treatment Visit 2.

^c Subjects who prematurely withdraw from the study will undergo a Premature Discontinuation Visit (see Section 4.2.4).

^d For subjects who received their regularly inhaled asthma medications and/or SABA on the morning of the visit, spirometry and reversibility will be measured at Visit 1a, which will occur within 10 days of Visit 1. For subjects who do not meet reversibility criteria at Visit 1a, Visit 1b will be scheduled for a second reversibility test, to occur within 7 days. Subjects who do not meet reversibility criteria after the second attempt will be screen failed.

^e At all visits beyond Visit 1, note the time of the last dose of asthma medications. The visit must be rescheduled if the last dose of Ventolin was <48 hours before Visit 2, or if the last dose of Atrovent was <8 hours before Visit 2 or Visit 3.

^f Includes evaluation of height and weight at Visit 1.

^g A serum pregnancy test (β -human chorionic gonadotropin [β -hCG]) will be performed at Visit 1; urine β -hCG test will be performed before randomization at Visit 2 (for women of child-bearing potential only).

^h At Visit 1, prohibited asthma medications are to be stopped and asthma medications changed as specified in Section 7.7.2. At the end of Visit 3 (or upon premature discontinuation, if applicable), subjects will return to pre-study or other appropriate inhaled maintenance asthma medications.

ⁱ For subjects in the PK substudy only.

Table 2 Timed Assessments at Each Treatment Visit (Visit 2 and Visit 3)

	Pre-Dose (minutes)			Doses 1 through 4 (minutes)				Dose 5 (minutes)									
	-60	-30	0	15	30	0	15	30	60	120	180	240	300	360	480	600	720
SBP/DBP	X ^a			X			X	X	X	X	X	X	X	X			
12-lead ECG ^b	X ^a			X			X	X	X	X	X	X	X	X			
Sample collection for glucose and potassium	X ^a			X			X	X	X	X	X	X	X	X			
PK sample collection ^c		X		X			X	X	X	X	X	X	X	X	X	X	X
Spirometry	X	X				X ^d	X	X	X	X	X	X	X	X			
Study drug administration			X														

Abbreviations: DBP=diastolic blood pressure; ECG=electrocardiogram; PK=pharmacokinetic; SBP=systolic blood pressure.

Note: When post-dose data collection timepoints are concurrent, variables will be collected in the following order: blood pressure, ECG, samples for serum glucose and potassium, PK blood samples (if applicable), and spirometry.

^a Pre-dose assessment to be performed within 60 minutes before the first dose.

^b ECG assessment of QTc interval and heart rate.

^c For subjects in the PK substudy only.

^d The 30-minute spirometry assessment should be started at approximately 25 minutes post-dose to allow for completion of the test before the next dose, so as not to delay dosing.

4.1 Screening Period (Visits 1, and Visits 1a/1b if applicable)

For subjects who were receiving only SABA as needed before study entry, the minimum and maximum Screening Period will be 3 and 28 days, respectively. For subjects who were receiving regularly scheduled ICS or ICS/LABA before study entry, the minimum and maximum Run-in Period will be 14 and 28 days, respectively. The Screening Period should be as short as possible; however, the duration will be determined by the Investigator.

4.1.1 Visit 1

The following activities will be performed at Visit 1:

- Obtain informed consent
- Register subject in IWRS to obtain subject screening number
- Obtain demographic data, including age, race, smoking history, medical/surgical history, and age of onset of asthma
- Obtain medication history, including prior and concomitant medications (see Section 7.7)
- Obtain SBP and DBP (see Section 5.2.2)
- Conduct a complete physical examination (see Section 5.2.1)
- Confirm acceptable MDI device technique and provide training as necessary
- Confirm the subject satisfies inclusion/exclusion criteria (see Section 3.1 and Section 3.2)
- Obtain a 12-lead ECG (see Section 5.2.4)
- Obtain clinical laboratory blood samples, including blood sample for serum β -human chorionic gonadotropin (β -hCG) for all women of child-bearing potential (see Section 5.2.3)
- Discontinue the subject's baseline asthma medications and change to protocol-specified asthma medications as follows for both the Screening and randomized Treatment Periods (see Section 7.7.2.1):
 - For subjects receiving only SABA as needed: switch to Sponsor-provided Ventolin and Atrovent as needed for symptoms, as described in Section 1.4.
 - For subjects receiving regularly scheduled ICS or ICS/LABA: switch to Sponsor-provided Pulmicort Flexhaler (either 180 μ g or 360 μ g

BID, based on the subject's previous therapy; see [Table 6](#)). These subjects will also receive Sponsor-provided Ventolin and Atrovent as needed for symptoms.

- Record AEs (if any)
Note: AEs must be recorded during the Screening Period, that is, from the time of signing the ICF to the start of randomized study drug. Adverse events that occur during the Screening Period will be recorded as medical history and not as study AEs unless they meet the definition of an SAE (see definition in [Section 6.2](#)).

For subjects who **have not taken** their regular morning doses of inhaled asthma maintenance medications and/or SABA within the previous 6 hours, the following activity will also be performed at Visit 1:

- Conduct spirometry assessments (FEV₁) (see [Section 5.1.2](#))
- Perform Ventolin reversibility test (described in [Section 5.1.3](#))

Note: For subjects who complete this reversibility test at Visit 1 and do not meet Ventolin reversibility criteria, Visit 1a will be scheduled for a second reversibility test.

For subjects who **have taken** their regular morning doses of inhaled asthma maintenance medications and/or SABA within the previous 6 hours before Visit 1 or any of the medications listed in [Table 8](#) within the washout periods listed in [Table 8](#), Visit 1a will be scheduled to allow for washout of asthma medications before spirometry and reversibility testing.

4.1.2 Visit 1a

The following activities will be performed at Visit 1a for subjects who did not complete spirometry at Visit 1 or who do not have a reversibility test at Visit 1 or who fail to meet reversibility criteria at Visit 1. Visit 1a will be scheduled to occur within 10 days of Visit 1.

- Review clinical laboratory results from Visit 1
- Review concomitant medications (see [Section 7.7](#))
- Confirm the subject satisfies inclusion/exclusion criteria (see [Section 3.1](#) and [Section 3.2](#))
- Perform Ventolin reversibility test (described in [Section 5.1.3](#))
- Record AEs (if any)

4.1.3 Visit 1b

Visit 1b may only be scheduled for subjects who did not perform Ventolin reversibility testing at Visit 1 and who did not meet Ventolin reversibility criteria at Visit 1a.

For subjects who do not meet reversibility criteria at Visit 1a, Visit 1b will be scheduled to occur within 10 days of Visit 1a for a second reversibility test. Only 2 reversibility attempts will be allowed. Subjects who do not meet reversibility criteria after the second attempt will be screen failed.

The following activities will be performed at Visit 1b for subjects who do not meet reversibility criteria at Visit 1a:

- Review concomitant medications (see Section 7.7)
- Confirm the subject satisfies inclusion/exclusion criteria (see Section 3.1 and Section 3.2)
- Perform Ventolin reversibility test (described in Section 5.1.3)
- Record AEs (if any)

4.2 Treatment periods

4.2.1 General guidance for Visits 2 and 3

- At the start of each Treatment Visit, prior to any study procedures being performed, site personnel must confirm the subject has withheld all asthma medications. The last Pulmicort Flexhaler dose should be the previous night (ie, the morning dose should be held). The last dose of Ventolin should be no later than 48 hours before Visit 2. The last dose of Atrovent should be no later than 8 hours before Visit 2 and Visit 3. Confirm the last time of dosing. **Note:** Subjects who have not withheld their Ventolin and Atrovent as described above before the study visit must have their visit rescheduled as soon as is practical, but within the specified visit window (± 2 days) [REDACTED]
- At Visit 2, the first dose of study drug will be administered before 10 am. At Visit 3, the first dose of study drug will be administered before 10 am and within 1 hour of the time administered at Visit 2. At each visit, subsequent doses will be administered at 30-minute intervals.
- Before Visits 2 and 3, sites should call the subject to remind the subject of the following:
 - 3 days before the visit:
 - Ventolin should be held for the time period described above
 - The day before the visit:

- Atrovent and Pulmicort Flexhaler should be held for the time periods described above
 - Bring their Sponsor-provided Ventolin (Visit 2 only), Atrovent, and Pulmicort Flexhaler, if assigned, with them to the clinic
 - Refrain from ingesting xanthine-containing foods and beverages and caffeine-containing medications for at least 6 hours before each study visit and for the duration of each study visit (see Section 3.8.2)
- Study drug should be dispensed as follows:
 - At 15 to 30 minutes before dosing, the seal around the study day treatment box should be opened and the instructions for administration of study drug on the inner flap of the study day treatment box should be followed
 - Refer to Section 7.2.1 for detailed instructions for preparation of treatments for administration. These instructions are to be adhered to and are relevant to all study treatment visits
 - Subject will administer the dose of assigned study drug at the clinic
- The in-clinic dosing time will be recorded as the time of administration of the last actuation of study drug for each dose
- Site personnel will instruct subjects not to take any non-study asthma medications without site personnel permission during a visit, until all study procedures have been completed and the subject is discharged. Site personnel should take every precaution to prevent use of non-study asthma medications during the test day. Site personnel may request the subject to surrender all non-study asthma medications at the start of the visit before performing any study procedures and return them to the subject at the end of the visit when all study procedures are completed.
- If a subject is experiencing severe symptoms and requires Ventolin or Atrovent for relief of asthma symptoms at any time during a study visit, site personnel must note the time and justification for use in the subject's chart and all spirometry assessments and further dosing should be stopped during the current Treatment Visit. Safety assessments should be continued at the discretion of the Investigator.

4.2.2 Visit 2 (Randomization Visit, Treatment Period 1)

The following should be performed before randomization at Visit 2:

- Collect Ventolin (subjects will continue to use Atrovent for rescue, not Ventolin, throughout the randomized Treatment Period)
- Perform a urine pregnancy test
- Confirm randomization criteria (Section 3.3.1) including pre-dose spirometry assessments (see Section 5.1.2)
- Review concomitant medications
- Review clinical laboratory results from Visit 1
- Record AEs (if any)

Note: Pre-randomization AEs are to be recorded as part of the medical history unless the event meets the definition of an SAE (see definition in Section 6.2).

- Confirm acceptable MDI device technique
- Register subject in IWRS to obtain subject randomization number. The subject is to be considered randomized after receiving a randomization number from the IWRS.

The following activities are to be performed after randomization:

- Perform pre-dose SBP and DBP assessments (see Section 5.2.2)
- Perform pre-dose ECG assessment (see Section 5.2.4)
- Collect pre-dose blood samples for serum glucose and potassium (see Section 5.2.3)
- For subjects in the PK substudy only: collect pre-dose PK sample (see Section 5.4.1)
- Dispense study drug (see Section 7.2) based on subject treatment assignment information from IWRS, at the timepoints specified in Table 2
- Perform post-dose SBP and DBP assessments after each study drug dose, at the timepoints specified in Table 2 (see Section 5.2.2)
- Perform post-dose ECG assessment after each study drug dose at the timepoints specified in Table 2 (see Section 5.2.4)
- Collect post-dose blood samples for serum glucose and potassium after each study drug dose at the timepoints specified in Table 2 (see Section 5.2.3)

- For subjects in the PK substudy only: collect post-dose PK sample after each study drug dose, at the timepoints specified in [Table 2](#) (see Section [5.4.1](#))
- Perform post-dose spirometry assessments at the timepoints specified in [Table 2](#) (see Section [5.1.2](#))
- Record AEs (if any)
- Schedule Visit 3, allowing for a Washout Period of 3 to 7 days
- Assure that the subject has enough Sponsor-provided asthma medication to last until the next Treatment Visit (Atrovent, and Pulmicort Flexhaler 180 µg or 360 µg for those subjects who were on ICS or ICS/LABA before study entry)

4.2.3 Visit 3 (Treatment Period 2)

The following should be performed before any other activities:

- Confirm eligibility criteria (see Section [3.1](#) and Section [3.2](#))
- Review concomitant medications
- Confirm acceptable MDI device technique

Then the following activities are to be performed:

- Perform pre-dose SBP and DBP assessments (see Section [5.2.2](#))
- Perform pre-dose ECG assessment (see Section [5.2.4](#))
- Collect pre-dose blood samples for serum glucose and potassium (see Section [5.2.3](#))
- Perform pre-dose spirometry assessments (see Section [5.1.2](#)) and confirm that the subject meets FEV₁ baseline stability criteria (see Section [5.1.4](#))
- For subjects in the PK substudy only: collect pre-dose PK sample (see Section [5.4.1](#))
- Dispense study drug (see Section [7.2](#)) based on subject treatment assignment information from IWRS at the timepoints specified in [Table 2](#)
- Perform post-dose SBP and DBP assessments after each study drug dose at the timepoints specified in [Table 2](#) (see Section [5.2.2](#))

- Perform post-dose ECG assessment after each study drug dose at the timepoints specified in [Table 2](#) (see Section [5.2.4](#))
- Collect post-dose blood samples for serum glucose and potassium after each study drug dose at the timepoints specified in [Table 2](#) (see Section [5.2.3](#))
- For subjects in the PK substudy only: collect post-dose PK sample after each study drug dose at the timepoints specified in [Table 2](#) (see Section [5.4.1](#))
- Perform post-dose spirometry assessments at the timepoints specified in [Table 2](#) (see Section [5.1.2](#))
- Conduct a complete physical examination (see Section [5.2.1](#))
- Record AEs (if any)
- Collect all unused Sponsor-provided asthma medication (Sponsor-provided, Atrovent, and Pulmicort Flexhaler, if applicable)
- Schedule the follow-up telephone call (see Section [4.3.1](#))
- Return subjects to their pre-study asthma maintenance medication regimen or other appropriate asthma medications

4.2.4 Premature Study Withdrawal Visit

See Section [4.3.2](#). The following activities should occur at the Premature Withdrawal from Visit:

- Review concomitant medications
- Perform SBP and DBP assessments (see Section [5.2.2](#))
- Conduct a complete physical examination (see Section [5.2.1](#))
- Obtain a 12-lead ECG (see Section [5.2.4](#))
- Obtain clinical laboratory blood samples for serum glucose and potassium (see Section [5.2.3](#))
- Record AEs (if any)
- Collect all unused Sponsor-provided asthma medication (Sponsor-provided Ventolin, Atrovent, and Pulmicort Flexhaler, if applicable)
- Return subjects to their usual pre-study asthma maintenance medication regimen

- Schedule the follow-up telephone call (see Section [4.3.1](#))

4.3 Follow-up period

4.3.1 Follow-up telephone call

Subjects will be contacted by study personnel through a telephone call 3 to 7 days after the last dose of study drug to assess AEs and SAEs, if any.

4.3.2 Premature withdrawal from the study

Complete the study completion page of the eCRF and record the reason for premature study withdrawal. The following categories should be used to describe these events in the eCRF:

- Subject discretion (document reason)
- Investigator considers it to be in the best interest of the subject
- AEs
- Administrative reasons (eg, early termination of the study)
- Subject lost to follow-up
- Major protocol deviation
- Death
- Protocol-specified criteria such as use of prohibited medications (refer to Section [7.7.3](#)).

5. STUDY ASSESSMENTS

The iDatafax system will be used for data collection and query handling. The Investigator will ensure that data are recorded on the eCRFs as specified in the clinical study protocol and in accordance with the instructions provided.

The Investigator ensures the accuracy, completeness, and timeliness of the data recorded and of the provision of answers to data queries according to the clinical study agreement. The Investigator will sign the completed eCRFs. A copy of the completed eCRFs will be archived at the study site.

5.1 Efficacy assessments

Efficacy will be assessed by PFTs. Forced expiratory spirometry for derivation of FEV₁ as defined in ATS/ERS guidelines will be performed in accordance with ATS criteria

(Appendix A) using a spirometer that meets or exceeds minimum performance recommendations of the ATS (see Appendix B).

5.1.1 Standardization of spirometry

To standardize spirometry, all sites will be provided with identical spirometry systems [REDACTED] with customized, study-specific software. Every effort will be made to provide all sites with standardized spirometry equipment. The volume accuracy of the spirometer is to be checked daily with appropriate documentation in a calibration log prior to the conduct of PFTs on each test day.

The volume accuracy of the spirometer is checked using a 3 L syringe across 3 flow ranges (ie, low, medium, and high flows), with temperature and barometric pressure correction. The calibration syringe must meet ATS specifications and not be used beyond the expiry date. Required accuracy is $\pm 3\%$ (ie, 3.09 L to 2.91 L; ATS/ERS). The results will be printed and maintained in a calibration log, which will be monitored for compliance during the monitoring visits (Appendix B).

All study staff responsible for performing PFTs will receive standardized training at an Investigator meeting. All technicians are required to demonstrate proficiency in the use of the equipment and the ability to perform technically acceptable PFTs (ATS criteria) prior to performing PFTs on study subjects (Miller et al 2005). After each test is performed, the spirometry software will provide immediate feedback to the technician indicating whether the effort meets ATS acceptability and repeatability standards (Appendix B). All PFT testing will be stored electronically. After completion of testing, the study staff will electronically transmit the spirometric measurements for centralized quality assurance review [REDACTED]. Feedback on the quality of the measurements will be provided to the investigational site and to the Sponsor or designee for central data management.

5.1.2 Assessment of FEV₁

Spirometry will be conducted at all visits except the Premature Discontinuation Visit (when applicable).

Spirometry at Visits 1, 1a, and/or 1b, and 2 will be used to satisfy enrollment and randomization criteria. Multiple forced expiratory efforts (at least 3 but no more than 8) will be performed and the 2 best efforts that meet the ATS/ERS acceptability and reproducibility criteria will be recorded. The best efforts will be based on the highest FEV₁. The average of these 2 assessments will be used to calculate the screening FEV₁.

[REDACTED] Spirometry will be conducted 60 minutes and 30 minutes before study drug administration. The average of these 2 assessments will be used to calculate morning pre-dose FEV₁.

Following study drug administration at Visits 2 and 3, spirometry will be performed at 30 minutes after each of the first 4 cumulative doses, and at 15, 30, 60, 120, 180, 240, 300,

and 360 minutes after the last dose. Three tests will be performed at each timepoint. The highest value at each timepoint will be used for these post-dose assessments.

5.1.3 Characterization of reversibility

Reversibility to Ventolin will be evaluated at Visit 1, 1a, and/or 1b. Subjects must demonstrate reversibility to Ventolin to be randomized in the study; no more than 2 reversibility test attempts are allowed. Reversibility testing is performed as follows:

1. Determine if morning doses of all maintenance asthma ICS/LABA, if applicable, were withheld and that short-acting bronchodilators were not administered within 6 hours of testing
2. Perform pre-bronchodilator PFTs at 30 minutes before administration of Ventolin
3. Administer 2 actuations of Ventolin (90 µg per actuation; total 180 µg)
4. Perform post-bronchodilator PFTs 30 minutes after the administration of Ventolin

Reversibility will be a comparison of the best FEV₁ effort obtained at 30 minutes pre-bronchodilator to the best FEV₁ effort obtained at 30 minutes post-bronchodilator following administration of Ventolin. A subject is considered reversible to Ventolin if the improvement in FEV₁ at 30 minutes post-Ventolin is $\geq 15\%$.

5.1.4 FEV₁ baseline stability criteria

It is important to ensure that lung function at each study visit is stable and reflective of asthma severity at randomization. As such, the average of the -60 minute and -30 minute FEV₁ values at Visit 3 must be within $\pm 20\%$ (absolute value) of the average of the -60 minute and -30 minute FEV₁ values at Visit 2. At Visit 3, if the pre-dose FEV₁ average is outside of the $\pm 20\%$ range, but the -30 minute assessment is within $\pm 22\%$, then another assessment may be conducted 30 minutes later. If the last 2 assessments meet the baseline stability requirements (ie, within $\pm 20\%$), the initial -60 minute pre-dose assessment will not be used and the last 2 assessments will be used to establish the eligibility criteria.

5.2 Safety assessments

Some safety assessments (serial SBP and DBP, QTcF intervals and HR from serial ECGs, and serial glucose and potassium concentrations) are also considered PD endpoints in this study. Safety will also be assessed by AEs and SAEs.

5.2.1 Medical/surgical history and physical examination

Medical and surgical history will be collected at Visit 1. A complete physical examination will be performed at Visits 1 and 3 or the Premature Discontinuation Visit, as applicable.

A complete physical examination will include the following: general appearance, skin, head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, chest, heart, abdomen, extremities, and nervous system. Additionally, weight, assessed in ordinary indoor clothing with shoes off, and height will be recorded at Visit 1 only ([Table 1](#)).

5.2.2 SBP and DBP

Blood pressure (SBP and DBP) will be measured at the timepoints shown in [Table 1](#) and [Table 2](#).

At all study visits (Visits 1 to 3 and the Premature Discontinuation Visit, if applicable), SBP and DBP will be assessed after the subject is supine or seated for 5 minutes. If, in the opinion of the Investigator, a clinically significant change occurs, then the measurement should be repeated at medically appropriate intervals until the value returns to within an acceptable range. If the value does not return to baseline, the Investigator should determine if this is an AE (see Section [6.1](#)).

5.2.3 Clinical laboratory testing

Blood will be collected for clinical laboratory testing at the timepoints shown in [Table 1](#) and [Table 2](#). A complete clinical chemistry panel will be performed at Visit 1 only ([Table 3](#)). Sites must evaluate clinical laboratory data before the subject is randomized. At all other timepoints (see [Table 2](#)), samples will be collected for the measurement of serum glucose and potassium. Additional blood may be drawn for assessment of glucose, potassium, or other laboratory parameters at any time at the discretion of the Investigator.

At Visits 2 and 3, before dosing, an indwelling venous cannula may be inserted. The study nurse will decide when to remove or replace the venous cannula based on the time (since insertion of the cannula) or if clotting occurs. If the cannula is removed, the subsequent blood samples will be collected by venipuncture or the cannula may be replaced. Subjects will be in a seated or supine position during blood collection.

Approximately 35 mL of blood will be collected per subject during the study for clinical laboratory tests. For subjects participating in the PK substudy, approximately 220 mL of blood will be collected at Visits 2 and 3 for PK analysis; a total of 255 mL of blood will be collected for subjects participating in the PK study. The exact blood volume collected may vary depending on laboratory procedures or changes in PK sampling. However, it will not exceed 300 mL per subject.

Clinical laboratory tests will be analyzed by a central laboratory according to standardized, validated assays. The laboratory will supply detailed procedures for the preparation and collection of blood samples along with all containers needed for their collection. Blood sample volumes will meet the laboratory's specification.

Table 3. List of Laboratory Tests to be Performed at Screening

Hematology

Hemoglobin	Platelet count
Hematocrit	Mean corpuscular hemoglobin
White blood cell count with differential	Mean corpuscular hemoglobin concentration
Red blood cell count	Mean corpuscular volume

Clinical chemistry

Liver enzyme and other liver function tests

Alanine aminotransferase
Aspartate aminotransferase
Alkaline phosphatase
Bilirubin, total
Gamma-glutamyl transferase

Other clinical chemistry

Albumin
Blood urea nitrogen
Calcium
Chloride
Cholesterol
Bicarbonate
Creatinine
Glucose
Magnesium
Potassium
Phosphate
Protein, total
Sodium
Triglycerides
Urea

Other tests:

β-hCG test for pregnancy^a

Creatinine clearance will be estimated by the CKD-EPI formula at Screening only.

Abbreviations: CKD-EPI=Chronic Kidney Disease Epidemiology Collaboration.

^a Serum β-hCG test will be performed in all women of childbearing potential at Visit 1. Urine β-hCG test will be performed at Visit 2 before randomization.

5.2.4 ECG

A single 12-lead ECG will be obtained at the timepoints shown in [Table 1](#) and [Table 2](#). The ECG parameters to be assessed at Visit 1 include HR, PR interval, QRS axis, QRS interval, and QT/QTcF interval. Sites must evaluate a subject's ECG data before the subject is randomized. At all other timepoints, only QTcF and HR will be assessed.

The QT intervals and calculated QTcF intervals will be reviewed and checked for gross inaccuracies by the Investigator or designated ECG reviewer.

To standardize ECG collection, all sites will be provided with identical ECG equipment [REDACTED] with customized study-specific software on a laptop. All study staff responsible for performing ECG collection will receive identical, detailed training at the Investigator meeting as well as site-phone training sessions. Each site is required to demonstrate proficiency in the use of the equipment and the ability to perform technically acceptable ECGs before performing testing on study subjects. After each test is performed, the site will electronically transfer the ECG data for centralized quality assurance review [REDACTED]. Feedback on the quality of the ECGs will be provided to the investigational site via a site qualification form.

5.3 Other assessments – not applicable

5.4 PK substudy

5.4.1 Collection of samples

For subjects in the PK substudy, blood samples for the determination of plasma concentrations of albuterol will be collected during treatment period at the timepoints listed in [Table 2](#).

At Visits 2 and 3, before dosing, an indwelling venous cannula will be inserted for the collection of PK and clinical laboratory samples (see Section 5.2.3). Samples will be collected, handled, labeled, stored, and shipped as detailed in the laboratory manual. Plasma samples will be analyzed for albuterol using a validated assay.

5.4.2 Determination of drug concentration

Samples for determination of albuterol concentrations in plasma will be analyzed by [REDACTED], using validated assays. Additional analyses may be conducted on the biological samples to further investigate the presence and/or identity of drug metabolites. Any results from such analysis will be reported separately from the clinical study report (CSR). Full details of the analytical method and analyses performed used will be described in a separate bioanalytical report.

5.4.3 Storage and destruction of PK samples

Pharmacokinetic samples will be disposed of after the bioanalytical report finalization or 6 months after issuance of the draft bioanalytical report (whichever is earlier), unless requested for future analyses.

Pharmacokinetic samples may be disposed of or destroyed and anonymized by pooling. Additional analyses may be conducted on the anonymized, pooled PK samples to further evaluate and validate the analytical method. Any results from such analyses may be reported separately from the CSR.

Incur sample reproducibility analysis, if any, will be performed alongside the bioanalysis of the test samples. The results from the evaluation will not be reported in the CSR but separately in a bioanalytical report.

5.5 Pharmacodynamics

Extrapulmonary PD parameters are SBP and DBP (Section 5.2.2), serum potassium and glucose (Section 5.2.3), and QTcF and HR (Section 5.2.4).

5.6 Genetics – not applicable

5.7 Biomarker analysis – not applicable

6. SAFETY REPORTING AND MEDICAL MANAGEMENT

The Principal Investigator is responsible for ensuring that all staff involved in the study are familiar with the content of this section.

6.1 Definition of AEs

The following definitions of terms are guided by the International Conference for Harmonisation (ICH) and the US Code of Federal Regulations (CFR) (21 CFR 312.32) and are included herein.

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE (also referred to as an adverse experience) can be any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. An AE can arise from any use of the drug (eg, off label use, use in combination with another drug) and from any route of administration, formulation, or dose, including an overdose.

Adverse events include, but are not limited to:

- any symptom or condition not previously reported by the subject (medical history)
- an exacerbation of a pre-existing symptom or condition
- a significant increase in frequency or intensity of a pre-existing episodic event or condition
- a drug interaction
- a condition first detected or diagnosed after study drug administration even though it may have been present prior to the start of the study

An AE does not include:

- medical or surgical procedures (eg, surgery, endoscopy, tooth extraction, blood transfusion); the condition that led to the procedure is an AE (eg, bleeding esophageal varices, dental caries)
- overdose of either study drug or concurrent medication without any clinical signs or symptoms
- non-clinically significant abnormal laboratory values (if accompanied by signs/symptoms, the signs or symptoms are considered an AE)

6.2 Definitions of SAE

An AE is considered “serious” if, in the view of the Investigator or Sponsor, it results in any of the following outcomes:

- death
- a life-threatening AE
- inpatient hospitalization or prolongation of existing hospitalization
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- a congenital anomaly/birth defect

Important medical events that may not result in death, be life threatening, or require hospitalization may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

Hospitalization for a pre-existing condition, including an elective procedure, which has not worsened, does not constitute an SAE.

An AE is considered “life-threatening” if, in the view of the Investigator or Sponsor, its occurrence places the patient or subject at immediate risk of death. It does not include an adverse reaction or suspected adverse reaction that, had it occurred in a more severe form, might have caused death.

For further guidance on the definition of a SAE, see [Appendix C](#).

6.3 Recording of AEs

6.3.1 Performing AE assessments

The Investigator is responsible for promptly documenting and reporting all AEs observed during the study in the subject's eCRF and on the AE Reporting Form. If the AE is unexpected, the Investigator should report the AE immediately to the Sponsor. In addition, certain AEs (as described in Section 6.2) are classified as 'serious' and must be reported no later than 24 hours after the Investigator recognizes/classifies the event as an SAE to the Sponsor or its designee.

In the case of SAEs, after discussing the details of the event, the Investigator and the Medical Monitor may discontinue the subject from randomized study drug.

6.3.2 Pre-randomization AEs

Adverse events occurring from the time the subject signs informed consent until the subject is randomized will be summarized as medical history and not as an AE unless the event meets the definition of an SAE as defined in Section 6.2.

6.3.3 AEs based on signs and symptoms

When collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately.

6.3.4 AEs based on examinations and tests

Many laboratory abnormalities observed during the course of a study will be included under a reported AE describing a clinical syndrome (eg, elevated blood urea nitrogen and creatinine in the setting of an AE of renal failure, or decreased hemoglobin in a case of bleeding esophageal varices). Isolated laboratory abnormalities should be reported as AEs if they are considered to be clinically significant by the Investigator.

If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result/vital sign will be considered as additional information. Wherever possible the reporting Investigator uses the clinical, rather than the laboratory term (eg, anemia versus low hemoglobin value). In the absence of clinical signs or symptoms, clinically relevant deteriorations in non-mandated parameters should be reported as AE(s).

Criteria for a "clinically significant" laboratory abnormality are:

- a laboratory abnormality that leads to study drug dose suspension or discontinuation
- a laboratory abnormality that results in any therapeutic intervention (ie, concomitant medication or therapy)

- any other laboratory abnormality judged by the Investigator to be of any particular clinical concern (eg, significant fall in hemoglobin not requiring transfusion)

For laboratory abnormalities that do not meet the above criteria but are outside of the normal reference range, the Investigator should indicate whether the value is clinically significant or not clinically significant for the subject.

Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the baseline assessment will be reported as an AE.

Paradoxical bronchospasm will be monitored by [REDACTED].

6.3.5 Disease under study

Symptoms of the disease under study are those which might be expected to occur as a direct result of the subject's asthmatic condition (eg, wheeze, breathlessness, cough). Events that are unequivocally due to the disease under study should not be reported as an AE during the study unless they meet SAE criteria or lead to discontinuation of study drug.

6.3.6 Severity

The Investigator must categorize the severity of each AE according to the following guidelines:

Mild: Associated with no limitation of usual activities or only slight discomfort; generally not requiring alteration or cessation of study drug administration; and/or not needing therapeutic intervention.

Moderate: Associated with limitation of usual activities or significant discomfort; generally requiring alteration or cessation of study drug administration; and/or requiring therapeutic intervention.

Severe: Associated with inability of subject to carry out usual activities or very marked discomfort; considered to be life-threatening; resulting in significant disability or incapacity; and requiring therapeutic intervention.

6.3.7 Relationship to study drug

The Investigator will assess causal relationship between the study drug and each AE, and answer 'yes' or 'no' to the question 'Do you consider that there is a reasonable possibility that the event may have been caused by the study drug?'

For SAEs, causal relationship will also be assessed for other medication and study procedures. Note that for SAEs that could be associated with any study procedure the causal relationship is implied as 'yes'.

A guide to the interpretation of the causality question is found in [Appendix C](#).

6.4 Reporting of SAEs

In agreeing to the provisions of this protocol, the Investigator accepts all legal responsibilities for AE identification, documentation, grading, assignment of causality, and prompt notification of SAEs to the Sponsor or designee. All SAEs must be reported to the Sponsor or designee no later than 24 hours after the Investigator recognizes/classifies the event as an SAE. All SAEs should be documented and reported using the eCRF. At a minimum, a description of the event and the Investigator's judgment of causality must be provided at the time of the initial report using the appropriate form (eg, SAE Report Form). After the initial report, as necessary, the Investigator must provide any additional information on an SAE to the Sponsor or designee within 2 working days after receiving the information. Follow up information will be a detailed written report that may include copies of hospital records, case reports, autopsy reports, and other pertinent documents.

For subjects discontinuing study drug, all AEs/SAEs will be collected through the follow-up telephone call.

Post-treatment SAEs following the last dose of study drug must be reported to the Sponsor as described in Section 6.4.3.

The Investigator is responsible for continuing to report any new or relevant follow-up information that s/he learns about the SAE.

6.4.1 Supplemental investigations of SAEs

The Investigator and supporting personnel responsible for subject care should discuss with the Sponsor Medical Monitor or designee any need for supplemental investigations of SAEs. If additional assessments are conducted, results must be reported to the Sponsor. If a subject dies during study participation and if a post mortem examination is performed, a copy of the autopsy report should be submitted to the Sponsor.

6.4.2 Post-study follow-up of AEs

Any AEs that are unresolved at the subject's last AE assessment in the study are to be followed up by the Investigator for as long as medically indicated, but without further recording in the eCRF. The Sponsor retains the right to request additional information for any subject with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.

6.4.3 Notification of post-treatment SAEs

Investigators are not obligated to actively follow subjects after completion of the study. However, if the Investigator becomes aware of a post-treatment SAE occurring within 5 to 7 days following the last dose of study drug, the SAE must be reported to the Sponsor, whether or not the event is attributable to study drug. All SAEs must be reported to the Sponsor no later than 24 hours after the Investigator recognizes/classifies the event as an SAE.

6.4.4 IRB notification of SAEs

The Investigator is responsible for promptly notifying her/his IRB of all SAEs, including any follow-up information, occurring at their site and any SAE regulatory report, including any follow-up reports, received from the Sponsor. Documentation of IRB submission must be retained for each safety report. The Investigator is also responsible for notifying the Sponsor if their IRB requires revisions to the ICF or other measures based on its review of an SAE Report.

6.4.5 Health Authority Safety Reports

The Sponsor or its representatives will submit a safety report to the appropriate regulatory agencies for any suspected adverse reaction that is both serious and unexpected within the timeframe specified by each regulatory agency.

The Sponsor or its representatives will send copies of each submitted safety report to Investigators actively participating in the Sponsor's clinical studies. Safety reports must also be submitted to the appropriate IRBs as soon as possible. Documentation of submission to the IRB must be retained for each safety report.

6.5 Overdose

An overdose is defined as any dose greater than the highest dose investigated in this study that results in clinical signs and symptoms. In the event of a study drug overdose, the Investigator should use their best clinical judgment in treating the overdose, and the Sponsor's Medical Monitor should also be contacted. Investigators should refer to the relevant document(s) for detailed information regarding warnings, precautions, contraindications, AEs, and other significant data pertaining to the study drug(s) being administered. Such document(s) may include but are not limited to the Investigator's Brochure for AS MDI and approved product labeling for open-label products.

6.6 Pregnancy

Any pregnancy that occurs from Visit 1 until study completion must be reported to the Sponsor. The pregnancy must be followed up to determine the outcome (including premature termination) and status of mother and child.

6.6.1 Maternal exposure

If a subject becomes pregnant during the course of the study, the study drug should be discontinued immediately.

Pregnancy itself is not regarded as an AE unless there is a suspicion that the investigational product under study may have interfered with the effectiveness of a contraceptive medication. Congenital abnormalities/birth defects and spontaneous miscarriages should be reported and handled as SAEs. Elective abortions without complications should not be handled as AEs. The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy,

normal birth or congenital abnormality) should be followed up and documented even if the subject was withdrawn from the study.

If any pregnancy occurs in the course of the study, then the Investigator or other site personnel should inform the appropriate Sponsor representatives immediately but **no later than 24 hours** of when he or she becomes aware of it.

Pregnancy should be recorded on a paper Pregnancy Report Form and reported by the Investigator to the Sponsor or designee. Pregnancy follow-up should be recorded on the same Pregnancy Report Form and should include possible relationship to the study drug in response to the pregnancy outcome. Any SAE experienced during pregnancy must be reported on the SAE Report Form.

The same timelines apply when outcome information is available.

6.6.2 Paternal exposure

Male subjects who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of randomized treatment until 2 weeks after their last dose, and must not donate sperm during their study participation period. If a male subject's partner becomes pregnant during the course of the study, it must be reported to the Sponsor within 24 hours of the Investigator learning of its occurrence.

6.7 Medication error

For the purposes of this clinical study a medication error is an unintended failure or mistake in the treatment process for a study drug that either causes harm to the subject or has the potential to cause harm to the subject.

A medication error is not lack of efficacy of the drug, but rather a human or process related failure while the drug is in control of the study site staff or subject.

Medication error includes situations where an error:

- occurred
- was identified and intercepted before the subject received the drug
- did not occur, but circumstances were recognized that could have led to an error

Examples of events to be reported in clinical studies as medication errors:

- drug name confusion
- dispensing error, eg, medication prepared incorrectly, even if it was not actually given to the subject

- drug not administered as indicated, for example, wrong route or wrong site of administration
- drug not taken as indicated, eg, tablet dissolved in water when it should be taken as a solid tablet
- drug not stored as instructed, eg, kept in the refrigerator when it should be at room temperature
- wrong subject received the medication (excluding IWRS errors)
- wrong drug administered to subject (excluding IWRS errors)

Examples of events that **do not** require reporting as medication errors in clinical studies:

- errors related to or resulting from IWRS, including those which lead to one of the above listed events that would otherwise have been a medication error
- subject accidentally missed drug dose(s) (eg, forgot to take medication)
- accidental overdose (will be captured as an overdose)
- subject failed to return unused medication or empty packaging
- errors related to background and rescue medication, or standard of care medication in open label studies

Medication errors are not regarded as AEs but AEs may occur as a consequence of the medication error.

If a medication error occurs in the course of the study, then the Investigator or other site personnel informs the appropriate Sponsor representatives immediately but **no later than 24 hours** of when he or she becomes aware of it.

6.8 Management of study drug-related toxicities – not applicable

7. INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS

7.1 Identity of investigational product(s)

In this protocol, “study drug” refers to an active ingredient being tested or used as a reference in this study. Study drugs used in this study are summarized in [Table 4](#). Instructions for priming and use are provided in [Appendix D](#).

AS MDI is manufactured and supplied by the Sponsor. For open-label Proventil (active control), MDIs will be provided from commercial supplies. Manufacturer's instructions for study drug administration will be provided.

Table 4. Randomized Study Drugs

Product Name and Dose	Product Strength	Manufacturer	Dosage Form/ Fill Count	Administration
AS MDI 90 µg	AS MDI 90 µg/ actuation ^a	Pearl	MDI/ 120 actuations	Taken as 1, 2, 4, or 8 inhalations
Proventil 90 µg	Albuterol 90 µg/actuation ^a	Merck Sharp & Dohme Corp.	MDI/ 200 actuations	Taken as 1, 2, 4, or 8 inhalations

Note: All study drugs will be administered by oral inhalation.

^a Each inhalation contains 108 µg albuterol sulfate corresponding to 90 µg albuterol base per actuation

For the Sponsor-provided background asthma medication (Ventolin, Atrovent, and Pulmicort Flexhaler) and Ventolin for reversibility testing, commercial dry powder inhalers/MDIs with dose counters and manufacturer's instructions for use will be provided. These medications are listed in [Table 5](#).

Table 5. Other Sponsor-provided Study Medications

Product Name	Product Strength	Manufacturer	Dosage Form/ Fill Count	Administration
Atrovent	Ipratropium bromide 17 µg/actuation	Boehringer Ingelheim Pharmaceuticals	MDI/ 200 actuations	Used as needed for symptoms during the Screening and randomized Treatment Periods
Pulmicort Flexhaler	Budesonide 180 µg	AstraZeneca	DPI/ 120 actuations	1 or 2 inhalations BID, as directed at Visit 1
Ventolin	Albuterol 90 µg/actuation ^a	GlaxoSmithKline	MDI/ 200 actuations	Taken as directed for reversibility testing (Visits 1, 1a, or 1b) and as needed for symptoms during Screening

Abbreviations: DPI=dry powder inhaler.

Note: All study drugs will be administered by oral inhalation.

^a Each inhalation contains 108 µg albuterol sulfate corresponding to 90 µg albuterol base per actuation.

7.2 Dose and treatment regimens

Each of the 2 Treatment Visits will include 1 of the following cumulative dose treatments, based on the subject's randomized treatment assignment:

- AS MDI in cumulative doses: 1+1+2+4+8 actuations (90, 90, 180, 360, and 720 µg; 90 µg per actuation)
- Proventil in cumulative doses: 1+1+2+4+8 actuations (90, 90, 180, 360, and 720 µg; 90 µg per actuation)

7.2.1 Instructions for preparation of treatments for administration and dispensing

Priming should be done by study personnel in a room separate from the dosing and sampling areas. Blood sampling supplies must be kept in an area separate from the rooms where the priming and administration of AS MDI and Proventil take place. The indwelling cannula for collection of blood samples should be covered (eg, with plastic wrap) during dosing.

After the administration of AS MDI and Proventil, the subjects will clean their hands and faces with water or a wet wipe to remove any residual drug and avoid cross-contamination of blood sampling supplies. Study personnel will also clean their hands after dosing and/or handling of inhalers.

7.2.2 Randomized study drug

AS MDI

Individual AS MDIs will be packaged in a foil pouch and contained in an individual visit treatment box. Both the visit treatment box and the foil overwrap will have a label with a component ID number. Confirm that the identifier given by IWRS and the ID number written on the label are the same. The treatment box is labeled with a 2-part label. Write the subject number and treatment visit number on each part of the 2-part label. The tear-off part of the label is to be placed onto the IWRS confirmation report.

All MDIs must be primed by study personnel before the first use. Priming involves releasing 4 sprays into the air before the first use of the inhaler. Shaking and priming the inhaler fills a chamber inside the canister with the correct dose and mix of medication so that it is ready to use.

The MDI must be primed in a separate room from the subject treatment area. Since the MDI is primed in a separate room before dosing, there is a possibility that there may be a delay between priming and dosing, and therefore to ensure consistency in the administration for all subjects, the MDIs are to be gently shaken (5 to 10 seconds) immediately before each actuation (inhalation).

To prime the inhaler, gently shake the inhaler for 5 to 10 seconds and then spray once into the air away from yourself and others. Wait approximately 30 seconds and repeat the process 3 more times.

Each dose will consist of 1 to 8 actuations from the MDI. See [Appendix D](#) for instructions on the administration of AS MDI.

Open-label Proventil

Individual Proventil MDIs will be contained in an individual visit treatment box. The visit treatment box will have a 2-part label with a component ID number. Confirm that the identifier given by IWRS and the component ID number written on the label are the same. Write the subject number and treatment visit number on each part of the 2-part label. The tear-off part of the label is to be placed onto the IWRS confirmation report.

Proventil should be primed by study personnel (in a separate room from the subject treatment area) per manufacturer's instructions before administering to subject. Since Proventil is primed in a separate room before dosing, there is a possibility that there may be a delay between priming and dosing, and therefore to ensure consistency in the administration for all subjects, the MDIs are to be gently shaken (5 to 10 seconds) immediately before each actuation (inhalation).

Each dose will consist of 1 to 8 actuations from the MDI. See [Appendix D](#) for the manufacturer's instructions on the administration of Proventil.

7.2.3 Sponsor-provided background asthma therapies

Ventolin

Open-label Ventolin will be provided by the Sponsor and stored in a secured location within the clinic or pharmacy facilities. Ventolin should be stored at room temperature by the subject. Ventolin should be primed per manufacturer's instructions before dispensing to subject. See [Appendix D](#) for the manufacturer's instructions on the administration of Ventolin. Study personnel will record the number on the dose counter at the time of dispensing (following priming) and upon return.

Atrovent

Open-label Atrovent will be provided by the Sponsor and stored in a secured location within the clinic or pharmacy facilities. Atrovent should be stored at room temperature by the subject. Atrovent should be primed per manufacturer's instructions before dispensing to subject. See [Appendix D](#) for the manufacturer's instructions on the administration of Atrovent. Study personnel will record the number on the dose counter at the time of dispensing (following priming) and upon return.

Pulmicort Flexhaler

Open-label Pulmicort Flexhaler will be provided by the Sponsor and stored in a secured location within the clinic or pharmacy facilities. Pulmicort Flexhaler should be stored at room temperature by the subject. Pulmicort Flexhaler should be primed per manufacturer's instructions before dispensing to subject. See [Appendix D](#) for the manufacturer's instructions on the administration of Pulmicort Flexhaler. Study personnel will record the number on the dose counter at the time of dispensing (following priming) and upon return.

7.3 Labeling

All study drugs and other medications supplied by the Sponsor will be open-label. AS MDI will be packaged by the Sponsor.

7.3.1 Primary packaging and labeling

Labels will be prepared in accordance with Good Manufacturing Practice and local regulatory guidelines.

Open-label supplies (AS MDI and Proventil)

Open-label AS MDI and Proventil will be provided as individually labeled MDIs. Each MDI will contain a single label. The label will be printed with black ink and may include the following text:

Packaging Lot Trace ID #	Dosing Instructions
Space for entry of screening #	Storage Conditions
Component ID #	Compound ID - Protocol #
Space for entry of randomization #	Country regulatory requirements
Fill Count & Dosage Form	Sponsor address (if applicable)
Space for entry of Interval ID (Visit # only)	Translation Key (if applicable)
Re-evaluation/Expiration date (if applicable)	

7.3.2 Secondary packaging and labeling information (box)

AS MDI, open-label Proventil, open-label Ventolin, open-label Atrovent, and open-label Pulmicort Flexhaler supplies will be provided as 1 MDI per box. Box configuration is subject to change due to packaging constraints.

Each box will be labeled with a 2-part panel label printed with black ink and may include the following text:

Packaging Lot ID #	Dosing Instructions (if applicable)
Space for entry of screening #	Storage Conditions
Component ID #	Compound ID - Protocol #
Space for entry of randomization #	Country regulatory requirements
Kit Contents (1 MDI)	Sponsor address (If applicable)
Space for entry of Interval ID	Translation Key (If applicable)
Re-evaluation date (if applicable)	

7.4 Storage

All study drugs and Sponsor-provided medication should be kept in a secure place under appropriate storage conditions. The investigational product label specifies the appropriate storage. Commercially sourced medications (Proventil, Ventolin, Atrovent, and Pulmicort Flexhaler) should be stored as indicated on the respective product label.

Note: The clinical supplies storage area at the site must be monitored by the site staff for temperature consistency with the acceptable storage temperature range specified in the product label. Documentation of temperature monitoring should be maintained.

7.5 Compliance

The time of administration of randomized study drug will be recorded in the appropriate sections of the eCRF.

7.6 Accountability

Study personnel will have access to an IWRS to allocate subjects, to assign drug to subjects, and to manage the distribution of clinical supplies. Clinical supplies will be packaged according to a component schedule generated by the Sponsor or designee. Each person accessing the IWRS must be assigned an individual unique personal ID number (PIN). They must use only their assigned PIN to access the system and they must not share their assigned PIN with anyone.

The study drug provided for this study will be used only as directed in the clinical study protocol. Under no circumstances will the Investigator(s) allow the study drug to be used other than as directed by this protocol.

Investigational clinical supplies must be received by a designated person at the study site, handled and stored safely and properly, and kept in a secured location to which only the Investigator and designated assistants have access. Storage conditions for the clinical supplies should be observed, monitored, and documented. Clinical supplies are to be dispensed only in accordance with the protocol. The Investigator is responsible for keeping accurate records of the clinical supplies received from the Sponsor, the amount dispensed to and returned by the subjects, and the amount remaining at the conclusion of the study. Study drug should be handled in accordance with Good Pharmacy Practices. The Clinical Monitor should be contacted with any questions concerning investigational products where special or protective handling is indicated. At the end of the study, all clinical supplies including partial and empty containers must be returned as directed by the Sponsor.

Sites should check with the Sponsor representative for appropriate documentation that must be completed for drug accountability.

The Investigator or designated assistant should not open individual clinical supply containers until all pre-dose assessments have been completed and the subject is eligible to be randomized/continue with the study. Any deviation from this must be discussed with the Clinical Monitor.

For each subject, all used study drug materials will be collected. Used subject supplies will be kept at room temperature in a secure and locked cabinet until returned to the Sponsor or designee. **Note:** Used study drug will be stored separately from unused study drug.

7.7 Concomitant and other treatments

7.7.1 Prior medications

All prescription and over-the-counter medications, as well as any herbal or vitamin supplements, taken by the subject within 30 days of Visit 1 should be recorded on the Prior/Concomitant Medications eCRF page; indication, total daily dose, and route and dates of drug administration should be captured to the best of the subject's and site's ability.

Some subjects eligible for this study will be on regular inhaled asthma maintenance therapy defined as an ICS with or without a LABA with a stable dose for at least 30 days prior to Visit 1. The permitted total daily ICS dosage to qualify ICS usage for the 30 days prior to Visit 1, along with the assigned dose for Sponsor-provided Pulmicort Flexhaler, is defined in [Table 6](#).

Table 6 **Dose of Sponsor-provided Pulmicort Flexhaler to be Assigned Based on Pre-study ICS or ICS/LABA Dose**

Pre-study Asthma Inhaled Corticosteroid	Total Daily Dose of Pre-study Inhaled Corticosteroid (µg/day)	Dose of Sponsor-provided Pulmicort Flexhaler (µg/day)
Beclomethasone	100 to ≤200	360
Beclomethasone	>200 to ≤400	720
Budesonide	200 to ≤400	360
Budesonide	>400 to ≤800	720
Ciclesonide	80 to ≤160	360
Ciclesonide	>160 to ≤320	720
Fluticasone furoate	100	360
Fluticasone furoate	200	720
Fluticasone propionate	100 to ≤250	360
Fluticasone propionate	>250 to ≤500	720
Mometasone furoate	110 to ≤220	360
Mometasone furoate	>220 to ≤440	720
Triamcinolone acetonide	400 to ≤1000	360
Triamcinolone acetonide	>1000 to ≤2000	720

7.7.2 Concomitant medications

Any current ongoing medications, including over-the-counter medications and herbal supplements, will be allowed provided they are not explicitly prohibited by the protocol (Table 8 or Table 9). All concomitant medications taken during the study will be recorded on the Concomitant Medications eCRF page with indication, total daily dose, route of administration, and dates of drug administration. Any additions, deletions, or changes in the dose of these medications while in the study should be entered in the eCRF. Subjects should also be instructed to contact the Investigator if they develop any illnesses, especially those requiring medicinal intervention.

7.7.2.1 Required concomitant medications

Subjects who were receiving a regularly scheduled ICS or ICS/LABA before study entry will be switched to Pulmicort Flexhaler 180 µg or 360 µg BID, and LABA (if applicable) will be discontinued (Table 6). These subjects will continue to use Sponsor-provided Pulmicort Flexhaler 180 µg or 360 µg BID, as assigned at Visit 1, throughout the Screening Period and for the remainder of the study during both the randomized Treatment Periods and Washout Period.

No other asthma medications are allowed for the remainder of the study, except for Sponsor-provided Ventolin and Atrovent to be used as needed, as described in Section 1.4.

7.7.2.2 Allowed allergy medications

Table 7 lists allergy medications that are allowed as long as the subject has been on a stable dose for at least 30 days before Visit 1 and remains on a stable dose throughout the study.

Table 7 Allowed Allergy Medications

Non-sedating long-acting antihistamines ^a
Allergen immunotherapy
Intranasal corticosteroids
Intranasal antihistamines or combination products of intranasal antihistamines/corticosteroids

^a Short-acting antihistamines (eg, diphenhydramine) are also permitted for use as needed, but not regularly.

7.7.3 Prohibited medications

7.7.3.1 Prohibited asthma and allergy medications and washout periods

Specific prohibited asthma and allergy medications are listed in Table 8. Subjects taking any of these prohibited medications are required to stop taking them at Visit 1 and are required to attend Visit 1a for reversibility testing. The required washout period for each medication before Visit 1a is shown in Table 8.

Table 8 Prohibited Asthma and Allergy Medications That Must be Discontinued at Visit 1 and Required Washout Period Prior to the Next Visit

Medication	Minimum Washout Period Prior to the Next Visit
Short-acting muscarinic antagonist ^a	8 hours
Oral β 2-agonists	2 days
Theophylline	2 days
Cromoglycate	7 days
Nedocromil	7 days
Ketotifen ^b	7 days
Zileuton	7 days
LABAs ^c :	
Indacaterol, olodaterol, vilanterol	7 days
Salmeterol, formoterol	48 hours
Leukotriene receptor antagonist (eg, Singulair™)	7 days

^a Administered as fixed or loose combinations. **Note:** Atrovent is allowed for use during the study and must be discontinued at least 8 hours before each study visit.

^b Ketotifen eye drops are allowed; no washout required.

^c In combination with an ICS.

7.7.3.2 Prohibited non-asthma and non-respiratory medications

Subjects requiring medications presented in [Table 9](#) are prohibited from participating in this study. Subjects who recently discontinued use of these medications may be considered for study enrollment provided they have met the minimum cessation period prior to Visit 1. These medications are prohibited throughout the course of the study. If subjects require any of the prohibited medications listed in [Table 9](#), the Investigator should discuss with the monitor the suitability of the subject continuing study drug.

Note: Use of systemic corticosteroids (eg, oral, parenteral, intraocular, intraarticular) is prohibited for the duration of the study, including both the Screening and randomized Treatment Periods. If a subject requires a systemic corticosteroid to treat an asthma worsening or asthma exacerbation, the subject will be discontinued from study drug and withdrawn from the study.

Table 9 Prohibited Non-Asthma and Non-Respiratory Medications

Class of Medication	Minimum Cessation Period Prior to Visit 1 and Prohibited Throughout the Study
Any drug with potential to significantly prolong the QT interval ^{a,b}	14 days or 5 half-lives, whichever is longer
Other investigational drugs	30 days or 5 half-lives, whichever is longer
Non-selective non-ocular β -blocking agents	7 days
Cardiac anti-arrhythmics (Class Ia, III)	7 days, unless amiodarone, then 3 months
Anticonvulsants for seizure disorder ^c	Allowed if stable dose for 12 months and free of seizures for 1 year
Antipsychotic drugs ^d	30 days
Tricyclic antidepressants ^d	14 days
Monoamine oxidase inhibitors	14 days
Antitumor necrosis factor α antibodies (eg, infliximab and any other members of this class of drugs)	30 days or 5 half-lives, whichever is longer
Monoclonal antibodies ^e	30 days or 5 half-lives, whichever is longer
Protease inhibitors (eg, ritonavir)	30 days

Note: Benzodiazepines are not exclusionary. Serotonin norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors are not excluded as long as the subject has been on a stable dose for at least 30 days before Visit 1 and throughout the Screening and Treatment Phase, and the dose does not exceed the maximum recommended.

- ^a Subjects who are on medications that have the potential to prolong the QTc interval may be enrolled provided the dose has remained stable for at least 3 months before Visit 1, the subject meets all of the ECG inclusion criteria and none of the ECG exclusion criteria, and if, in the opinion of the Investigator, there are no safety concerns for the subject to participate in the study. Initiation of medications with the potential to significantly prolong the QT interval is prohibited throughout the Screening and Treatment Periods.
- ^b Short courses of macrolide and quinolone antibiotics to treat infections are permitted.
- ^c Anticonvulsants for conditions other than seizures may be started and stopped at any time before the study and throughout the Screening and Treatment Periods.
- ^d Antipsychotic agents and tricyclic antidepressants used for previously diagnosed underlying medical conditions are allowed if, in the opinion of the Investigator, there are no concerns regarding patient safety, and if the subject has been on a stable dose for at least 6 weeks.
- ^e Investigators should contact the Medical Monitor to determine the appropriateness and safety of continuing study drug on a case-by-case basis (eg, Prolia® [denosumab] for osteoporosis may be allowed after consultation).

7.7.4 Other concomitant treatment

Medication other than that described above, which is considered necessary for the subject's safety and wellbeing, may be given at the discretion of the Investigator and recorded in the appropriate sections of the eCRF.

8. STATISTICAL ANALYSES

8.1 Statistical considerations

Analyses will be performed by the Sponsor or its representatives. All analyses will be specified in a detailed statistical analysis plan (SAP) that will include table and data listing shells with mock graphical representations. The SAP will be signed before database lock.

Two-sided 90% confidence intervals (CIs) will be provided for all between-treatment comparisons.

8.2 Sample size estimate

Randomization of 38 subjects to achieve 30 subjects completing the study will provide 95% probability to demonstrate equivalence within ± 200 mL after all 5 cumulative doses (intersection-union test). This calculation assumes a true treatment difference (AS MDI–Proventil) of 35 mL, intra-subject standard deviation of 174 mL, and two one-sided 5% level tests (TOST).

Enrollment of 20 subjects to obtain 14 subjects completing the PK substudy will provide 95% probability to observe a one-sided upper 95% confidence bound for the C_{\max} ratio (AS MDI/Proventil) that is less than 1.50 even if the true ratio is as high as 1.15. This calculation assumes an intra-subject coefficient of variation of 22% for Proventil and a one-sided 5% test.

8.3 Definitions of analysis sets

The following analysis sets are defined in this study:

- The **Intent-To-Treat (ITT) analysis set** is defined as all subjects who are randomized to treatment and receive at least 1 dose of the study treatment. Subjects will be analyzed in each period according to the treatment they were assigned to per the randomization scheme (Note that a subject who used a study treatment but took less than 1 full dose of treatment will qualify for this analysis set).
- A **Modified ITT (mITT) analysis set** is a subset of the ITT analysis set including subjects who received treatment and have post-treatment efficacy data from both Treatment Periods. Data judged to be impacted by major protocol deviations will be determined prior to database lock and excluded per the statistical protocol deviation plan. Statistical tabulations and analyses will be by randomized treatment, but data obtained after subjects receive an incorrect treatment will be excluded from the affected periods.
- The **Safety analysis set** is defined as all subjects who are randomized to treatment and receive at least 1 dose of the study treatment. Subjects will be

analyzed according to treatment received rather than per the randomization scheme.

- The **Per Protocol** analysis set is a subset of the Safety analysis set including subjects who received treatment and have post-treatment extrapulmonary pharmacodynamic data. Data judged to be impacted by major protocol deviations will be determined prior to database lock and excluded per the statistical protocol deviation plan. Statistical tabulations and analyses will be by randomized treatment, but data obtained after subjects receive an incorrect treatment will be excluded from the affected periods.
- The **PK analysis set** is defined as subjects in the Safety analysis set who received study drug and for whom at least 1 primary PK parameter can be calculated and with no important protocol deviations thought to impact the analysis of the PK data.
- The **Not Randomized analysis set** is defined as subjects who did not receive a randomization number and therefore did not receive a dose of study treatment (eg, subjects who were screen failures or stopped participation before being randomized).

Demographics and baseline characteristics will be summarized for the ITT, mITT and Safety analysis sets. Extent of exposure will be summarized for the Safety analysis set. The Safety analysis set will be used to summarize AEs and SAEs.

Efficacy analyses of FEV₁ will be based on the mITT analysis set. The primary endpoint will also be analyzed using the ITT analysis set. The primary analyses of extrapulmonary PD parameters will be based on the Per Protocol analysis set. A supportive analysis of extrapulmonary PD will be conducted in the Safety analysis set as well. PK parameter analyses will be based on the PK analysis set.

8.4 Outcome measures for analyses

All efficacy assessments are relative to baseline and will be compared with Proventil. Refer to Section 2 for a complete delineation of efficacy and safety endpoints.

8.5 Methods for statistical analyses

8.5.1 Primary efficacy analysis

Change from baseline in FEV₁ 30 minutes post each of the cumulative doses will be analyzed using a linear mixed effect model with a random subject effect for the correlation across periods and an unstructured covariance matrix for the repeated measures within subject periods. In the event that the unstructured matrix fails to converge, the heterogeneous Toeplitz will be fit. The fixed effects will include treatment, baseline FEV₁, and period. Ninety-percent CIs will be calculated for the between-treatment differences after each cumulative dose and will be evaluated for containment within the equivalence bounds of ± 200 mL.

Baseline FEV₁ will be defined as the mean of available pre-dose values on the first day of each Treatment Period (ie, the mean of pre-dose values at Visits 2 and 3, where the mean of the -60 and -30 minute values for each visit day is obtained and then the average of the 2 visit means is obtained).

8.5.2 Secondary efficacy analysis

The FEV₁ AUC₀₋₆ is the area under the curve for change from baseline calculated using the trapezoidal rule and will be normalized by dividing the AUC by the length of follow up post the last cumulative dose (typically 6 hours). The FEV₁ AUC₀₋₆ will be analyzed using a linear mixed model with a random subject effect. The fixed effects in the model will include treatment, baseline FEV₁, and period. A 90% CI for the between-treatment difference will be calculated and assessed for containment with the equivalence bounds of ± 200 mL.

8.5.3 Data validation and transformation

In general, the distribution of spirometry measures is well approximated by a normal distribution. Under some circumstances, however (eg, during an exacerbation unrelated to treatment), extreme and atypical values can arise. Such values have high influence on estimation of variance parameters and on standard errors of fixed effect estimates. The distribution of scaled marginal residuals, and influence statistics will be examined to identify such cases. In the event that a single or small number of such outlying values are found to exist and found to be highly influential, the effects may be ameliorated by either transformation or removal of the outlier. Transformations to be considered may include the logarithmic transformation or normal rank transformations. Where outliers are removed, sensitivity analyses including those values will be reported.

Changes in spirometry measures from baseline, and from timepoint to timepoint will be examined graphically before database lock, as part of data quality management.

8.5.4 Extrapulmonary PD analysis

Extrapulmonary PD parameters of QTcF, HR, serum glucose, serum potassium, SBP, and DBP will each be analyzed using a similar model as described above for FEV₁ parameters post each cumulative dose. Between-treatment differences and corresponding 90% CIs will be provided.

Descriptive statistics (mean, median, standard deviation and range) for change from baseline for each scheduled assessment time, maximum change from baseline after the last cumulative dose, and time-weighted average change from baseline after the last cumulative dose will be tabulated by parameter and treatment. Baseline will be defined as the average of the values prior to dosing on the day of randomization. In addition, potentially clinically significant values will be identified and summarized.

8.5.5 PK substudy: PK analysis

8.5.5.1 PK parameters

Pharmacokinetic parameters will be estimated by noncompartmental analysis (NCA) using the software Phoenix[®] WinNonlin[®] (Certara, US). The PK analysis set will be used for the NCA. From the plasma albuterol concentration-time data, the following PK parameters will be estimated for each subject where possible:

AUC_{0-t}	The area under the plasma concentration-time curve from 0 to the time of the last measurable plasma concentration post the final cumulative dose
C_{max}	The maximum observed plasma concentration, expressed in concentration units post the final cumulative dose
T_{max}	The time to reach C_{max} , expressed in hours post the final cumulative dose
C_{15min}	The plasma concentration observed at 15 minutes post each cumulative dose

The AUC_{0-t} will be calculated using the linear-log trapezoidal method.

The PK parameters C_{max} and T_{max} will be obtained from the observed values.

8.5.5.2 Handling of values below the limit of quantification

Plasma concentration values which are reported as below the lower limit of quantification (LLQ) will be set to missing in the NCA. Actual sampling timepoints relative to dosing will be used for the NCA where available. If the actual sampling time is unknown, the scheduled protocol time may be used for the calculation of derived PK parameters. No formal “outlier” analysis is planned.

All values below LLQ will be assigned a value of $\frac{1}{2}$ LLQ for all descriptive statistics categories and mean plasma concentration profile plots.

8.5.5.3 Statistical analysis of PK data

Descriptive statistics for plasma concentrations of albuterol by treatment and nominal timepoint will be summarized on the linear and log-linear scale using the PK analysis set. Individual plasma concentrations at each nominal and actual timepoint for each treatment will be listed by subject using the Safety analysis set.

Natural log-transformed AUC_{0-t} and C_{max} values for albuterol post the final cumulative dose will each be analyzed with a linear mixed effects model containing fixed effects for treatment and period. Subject will be included as a random effect. Estimated geometric mean ratios with 90% CIs will be provided.

The $C_{15\text{min}}$ values for albuterol after each cumulative dose will be analyzed with a power law model. Natural log-transformed $C_{15\text{min}}$ will be regressed onto the natural log transformed cumulative dose levels. The model will include fixed effects for period and treatment, a random intercept, and possibly a random coefficient for log-cumulative dose.

8.5.6 Safety analyses

No formal statistical analysis of safety data is planned. Safety data will be summarized by treatment and listed.

Adverse events

Adverse events occurring during each Treatment Period will be summarized by the number of subjects experiencing an event and tabulated at the level of the Medical Dictionary for Regulatory Activities (MedDRA) system organ class and preferred term. The version of MedDRA current at the time of database lock will be used for the final analysis of data. Tabulations will be broken down by severity, seriousness, AEs leading to discontinuation, and by relationship to study drug. No hypothesis tests will be performed. Tables will show the overall incidence of AEs and the incidence for each treatment.

8.5.7 Handling of missing data

Pre-dose spirometry values will use the average of the non-missing -60 minute and -30 minute values.

The FEV_1 AUC_{0-6} will be calculated if there is at least 1 non-missing data point during the first 2 hours post-dose.

8.5.8 Statistical software

Data processing, statistical screening, descriptive reporting, and analysis of the efficacy and safety data will be performed using SAS (SAS Institute, Cary, NC, US; Version 9.3 or higher).

9. STUDY AND DATA MANAGEMENT BY THE SPONSOR

9.1 Training of study site staff

Before the first subject is entered into the study, a Sponsor representative will review and discuss the requirements of the clinical study protocol and related documents with the investigational staff and also train them in any study-specific procedures and study system(s) used.

The Principal Investigator will ensure that appropriate training relevant to the study is given to all of these staff, and that any new information relevant to the performance of this study is forwarded to the staff involved.

The Principal Investigator will maintain a record of all individuals involved in the study (medical, nursing and other staff).

9.2 Monitoring of the study

During the study, a Sponsor representative will have regular contacts with the study site, including visits to:

- provide information and support to the Investigator(s)
- confirm that facilities remain acceptable
- confirm that the clinical study team is adhering to the clinical study protocol, that data are being accurately and timely recorded in the eCRFs, that biological samples are handled in accordance with the Laboratory Manual and that study drug accountability checks are being performed
- perform source data verification (a comparison of the data in the eCRFs with the subject's medical records at the hospital or practice, and other records relevant to the study) including verification of informed consent of participating subjects. This will require direct access to all original records for each subject (eg, clinic charts)

The Sponsor representative will be available between visits if the Investigator(s) or other staff at the site needs information and advice about the study conduct.

9.2.1 Study agreements

The Principal Investigator at each site should comply with all the terms, conditions, and obligations of the clinical study agreement, or equivalent, for this study. In the event of any inconsistency between this clinical study protocol and the clinical study agreement, the terms of clinical study protocol shall prevail with respect to the conduct of the study and the treatment of subjects and in all other respects, not relating to study conduct or treatment of subjects, the terms of the clinical study agreement shall prevail.

Agreements between the Sponsor and the Principal Investigator should be in place before any study-related procedures can take place, or subjects are enrolled.

9.2.2 Archiving of study documents

The Investigator should follow the principles outlined in the Clinical Study Agreement.

9.3 Study timetable and end of study

The end of study is defined as the last subject's follow-up telephone call.

The study may be terminated at individual study sites if the study procedures are not being performed according to Good Clinical Practice (GCP), or if recruitment is slow.

9.4 Data management

Data management of the study will be performed by the Sponsor or designee, and supervised by the Sponsor.

10. ETHICAL AND REGULATORY REQUIREMENTS

10.1 Ethical conduct of the study

The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/GCP, applicable regulatory requirements and the AstraZeneca policy on Bioethics and Human Biological Samples.

10.2 Subject data protection

The ICF will incorporate (or, in some cases, be accompanied by a separate document incorporating) wording that complies with relevant data protection and privacy legislation.

10.3 Ethics and regulatory review

An IRB should approve the final clinical study protocol, the final version of the ICF, and any other written information and/or materials to be provided to the subjects. The opinion of the IRB should be given in writing.

The IRB should approve all advertising used to recruit subjects for the study.

The Sponsor will approve any modifications to the ICF that are needed to meet local requirements.

If required by local regulations, the clinical study protocol should be re-approved by the IRB annually.

Before enrollment of any subject into the study, the final clinical study protocol, including the final version of the ICF, is approved by the national regulatory authority or a notification to the national regulatory authority is done, according to local regulations.

Each Principal Investigator is responsible for providing the IRB with reports of any serious and unexpected adverse drug reactions from any other study conducted with the investigational product. The Sponsor will provide this information to the Principal Investigator so that he/she can meet these reporting requirements.

The head of the study site should seek the opinion of the IRB with respect to the appropriateness of continuing the study at the study site at least once a year when the duration of the study exceeds 1 year. The Principal Investigator should submit progress reports to the IRB via the head of the study site at the time of the clinical study protocol re-approval.

Before enrollment of any subject into the study, the final clinical study protocol, including the final version of the ICF, should be approved by the national regulatory authority with notification provided, according to local regulations. The Sponsor will handle the distribution of any of these documents to the national regulatory authorities.

The Sponsor will provide regulatory authorities, IRB, the head of the study site and the Principal Investigator with safety updates/reports according to local requirements.

10.4 Informed consent

The Principal Investigator(s) at each study site will:

- ensure each subject is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study
- ensure each subject is notified that they are free to discontinue from the study at any time
- ensure that each subject is given the opportunity to ask questions and allowed time to consider the information provided
- ensure each subject provides signed and dated informed consent before conducting any procedure specifically for the study
- ensure the original, signed ICF(s) is/are stored in the Investigator's Study File
- ensure a copy of the signed ICF is given to the subject
- ensure that any incentives for subjects who participate in the study as well as any provisions for subjects harmed as a consequence of study participation are described in the ICF that is approved by an IRB

10.5 Changes to the clinical study protocol and ICF

Study procedures will not be changed without the mutual agreement of the Coordinating Investigator and the Sponsor.

If there are any substantial changes to the clinical study protocol, then these changes will be documented in a new version of the study protocol.

The new version of the clinical study protocol is to be approved by the relevant IRB and if applicable, also the national regulatory authority approval, before implementation. Local requirements are to be followed for new versions of clinical study protocols.

The Sponsor will distribute any new versions of the clinical study protocol to each Principal Investigator(s). For distribution to the IRBs see Section [10.3](#).

If a change to a clinical study protocol requires a change to a site's ICF, the Sponsor and the site's IRB are to approve the revised ICF before the revised form is used.

10.6 Audits and inspections

Authorized representatives of the Sponsor, a regulatory authority, or an IRB may perform audits or inspections at the study site, including source data verification. The purpose of an audit or inspection is to systematically and independently examine all study-related activities and documents, to determine whether these activities were conducted, and data were recorded, analyzed, and accurately reported according to the clinical study protocol, GCP, guidelines of the ICH, and any applicable regulatory requirements. The Investigator will contact the Sponsor immediately if contacted by a regulatory agency about an inspection at the site.

11. LIST OF REFERENCES

Ahrens 1984

Ahrens RC, Smith GD. Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use. *Pharmacotherapy* 1984;4(3):105-121.

ATS/ERS Task Force 2005

ATS/ERS Task Force: Standardization of Lung Function Testing: Number 2 in Series. *European Respiratory Journal*. 2005;26(2):319-338.

EPR-3 2007

Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma—Summary Report. *J Allergy Clin Immunol* 2007;120(5 suppl):S94-138.

Global Initiative for Asthma 2017

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. Available from: www.ginasthma.org. Accessed 10 August 2017.

Miller et al 2005

Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005;26(2):319-338.

Philipson 2002

Philipson LH. β -Agonists and metabolism. *J Allergy Clin Immunol* 2002;110(6 suppl):S313-S317.

PROVENTIL HFA package insert

PROVENTIL HFA (albuterol sulfate) inhalation aerosol [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2014.

Tripp et al 2008

Tripp K, McVicar WK, Nair P, et al. A cumulative dose study of levalbuterol and racemic albuterol administered by hydrofluoroalkane-134a metered-dose inhaler in asthmatic subjects. *J Allergy Clin Immunol* 2008;122(3):544-549.

Appendix A Spirometry Assessment Criteria

Spirometry Assessment Criteria

Acceptable Versus Usable Tests


Acceptable Tests must meet the following Criteria:

1. Acceptable start of exhalation with brisk upstroke, no hesitation or false start, and EV < 5% of FVC or 0.150 L, whichever is the greater (see example in Figure A2-1)
2. No cough during the first second
3. No valsalva maneuver
4. No leak
5. No obstruction of mouthpiece
6. No extra breaths
7. Plateau achieved, ie., the volume-time curve shows no change in volume (<0.025 L) for ≥ 1 s, and the subject has tried to exhale for at least 6 seconds

An acceptable test meets all seven criteria listed. This is to be considered the “gold standard”.

Usable spirometry tracings are those that only meet criteria 1 and 2. When this occurs, repeat testing up to eight attempts for pre-dose and five attempts for post-dose assessments, in an effort to obtain three acceptable spirograms. If only usable tests are obtained, report results based on the three best usable trials with observed limitations.

Figure A2-1 Example of a Usable Spirogram



The expanded version of the early part of a subject's volume-time spirogram, illustrating back extrapolation through the steepest part of the curve, where flow is PEFR, to determine the new "time zero". Forced vital capacity -4.291 L; EV – 0.123 L (2.9% FVC): back extrapolation line through PEF.

Between-Maneuver Reproducibility Criteria

Pre-dose Assessments

After **three** acceptable spirometers have been obtained, apply the following tests:

The two largest values of FVC must be within 0.150 L of each other

The two largest values of FEV₁ must be within 0.150 L of each other

If these criteria are met, the spirometry testing for that time point may conclude. The highest FEV₁ and the highest FVC obtained at each testing time point (even if from different reproducible tracings), will be collected.

If acceptability criteria are not met, continue testing until they are met or the subject cannot/ should not continue (maximum of eight attempts).

Post-dose Assessments

After **two** acceptable spirometers have been obtained, apply the following tests:

The two largest values of FVC are within 0.150 L of each other and/or

The two largest values of FEV₁ are within 0.150 L of each other

If these criteria are met, the spirometry testing for that time point may conclude. The highest FEV₁ and the highest FVC obtained at each testing time point (even if from different reproducible tracings), will be collected.

If acceptability/reproducibility criteria are not met, continue testing until they are met or the subject cannot/ should not continue (maximum of five attempts).

Appendix B Spirometry Performance Recommendations

Spirometry Performance Recommendations

Spirometry data of the highest quality must be obtained for proper interpretation of the results of this protocol. To these ends, a standard spirometer will be used (provided by Pearl Therapeutics), central training provided, qualification will be required, and specific operating instruction will also be provided.

Source: [ATS/ERS Task Force 2005](#)

FEV₁ MANEUVERS

Equipment Requirements

The spirometer must be capable of accumulating volume for ≥ 15 s (longer times are recommended) and measuring volumes of ≥ 8 L (body temperature (ie, 37°C), ambient pressure saturated with water vapor, BTPS) with an accuracy of at least $\pm 3\%$ of reading or ± 0.050 L, whichever is greater, with flows between 0 and $14 \text{ L}\cdot\text{s}^{-1}$. The total resistance to airflow at $14.0 \text{ L}\cdot\text{s}^{-1}$ must be $< 1.5 \text{ cmH}_2\text{O L}^{-1}\cdot\text{s}^{-1}$ ($0.15 \text{ kPa L}^{-1}\cdot\text{s}^{-1}$). The total resistance must be measured with any tubing, valves, pre-filter, etc. included that may be inserted between the subject and the spirometer. Some devices may exhibit changes in resistance due to water vapor condensation, and accuracy requirements must be met under BTPS conditions for up to 8 successive FVC maneuvers performed in a 10-minute period without inspiration from the instrument.

Display

For optimal quality control, both flow–volume and volume–time displays are useful, and test operators should visually inspect the performance of each maneuver for quality assurance before proceeding with another maneuver. This inspection requires tracings to meet the minimum size and resolution requirements set forth in this standard. Displays of flow versus volume provide more detail for the initial portion (first 1 s) of the FVC maneuver. Since this portion of the maneuver, particularly the peak expiratory flow rate (PEFR), is correlated with the pleural pressure during the maneuver, the flow–volume display is useful to assess the magnitude of effort during the initial portions of the maneuver. The ability to overlay a series of flow–volume curves registered at the point of maximal inhalation may be helpful in evaluating repeatability and detecting sub-maximal efforts. However, if the point of maximal inhalation varies between blows, then the interpretation of these results is difficult because the flows at identical measured volumes are being achieved at different absolute lung volumes. In contrast, display of the FVC maneuver as a volume–time graph provides more detail for the latter part of the maneuver. A volume–time tracing of sufficient size also allows independent measurement and calculation of parameters from the FVC maneuvers. In a display of multiple trials, the sequencing of the blows should be apparent to the user. For the start of test display, the volume–time display should include ≥ 0.25 s, and preferably 1 s, before exhalation starts (zero volume). This time period before there is any change in volume is needed to calculate the back extrapolated volume (EV) and to evaluate effort during the initial portion of the

maneuver. Time zero, as defined by EV, must be presented as the zero point on the graphical output. The last 2 s of the maneuver should be displayed to indicate a satisfactory end of test.

When a volume–time curve is plotted as hardcopy, the volume scale must be $\geq 10 \text{ mm L}^{-1}$ (BTPS). For a screen display, 5 mm L^{-1} is satisfactory (Table A1-1).

Table A1-1. Recommended Minimal Scale Factors for Time, Volume and Flow on Graphical Output

Parameter	Instrument Display		Hardcopy Graphical Output
	Resolution Required	Scale Factor	Resolution Required
Volume*	0.050 L	5 mm-L^{-1}	0.050 L
Flow*	0.200 L-s^{-1}	$2.5 \text{ mm L}^{-1} \text{ s}^{-1}$	0.200 L-s^{-1}
Time	0.2 s	10 mm-s^{-1}	0.2 s

*The correct aspect ratio for flow versus volume display is 2 units of flow per 1 unit of volume

The time scale should be $\geq 20 \text{ mm-s}^{-1}$, and larger time scales are preferred ($\geq 30 \text{ mm-s}^{-1}$) when manual measurements are made. When the volume–time plot is used in conjunction with a flow–volume curve (ie., both display methods are provided for interpretations and no hand measurements are performed), the time scale requirement is reduced to 10 mm-s^{-1} from the usually required minimum of 20 mm-s^{-1} (Table A1-1). The rationale for this exception is that the flow–volume curve can provide the means for quality assessment during the initial portion of the FVC maneuver. The volume–time curve can be used to evaluate the latter part of the FVC maneuver, making the time scale less critical.

Validation

It is strongly recommended that spirometry systems should be evaluated using a computer-driven mechanical syringe or its equivalent, in order to test the range of exhalations that are likely to be encountered in the test population. Testing the performance of equipment is not part of the usual laboratory procedures.

Quality Control

Attention to equipment quality control and calibration is an important part of good laboratory practice. At a minimum, the requirements are as follows: 1) a log of calibration results is maintained; 2) the documentation of repairs or other alterations which return the equipment to acceptable operation; 3) the dates of computer software and hardware updates or changes; and 4) if equipment is changed or relocated (eg, industrial surveys), calibration checks and quality-control procedures must be repeated before further testing begins.

Key aspects of equipment quality control are summarized in [Table A1-2](#).

Table A1-2. Summary of Equipment Quality Control

Test	Minimal Interval	Action
Volume	Daily	Calibration check with a 3 L syringe
Leak	Daily	2 cm H ₂ O (0.3 kPa) constant pressure for 1 minute
Volume Linearity	Quarterly	1 L increments with a calibrating syringe measured over the entire volume range
Flow Linearity	Weekly	Test at least 3 different flow ranges
Time	Quarterly	Mechanical recorder check with stop watch
Software	New versions	Log installation date and perform test using “known” subject

Calibration is the procedure for establishing the relationship between sensor-determined values of flow or volume and the actual flow or volume. A calibration check is different from calibration and is the procedure used to validate that the device is within calibration limits, eg, $\pm 3\%$ of true. If a device fails its calibration check then new calibration procedure or equipment maintenance is required. Calibration checks must be undertaken daily, or more frequently, if specified by the manufacturer. The syringe used to check the volume calibration of spirometers must have an accuracy of ± 15 mL or $\pm 0.5\%$ of the full scale (15 mL for a 3-L syringe), and the manufacturer must provide recommendations concerning appropriate intervals between syringe calibration checks. Users should be aware that a syringe with an adjustable or variable stop may be out of calibration if the stop is reset or accidentally moved. Calibration syringes should be periodically (eg, monthly) leak tested at more than 1 volume up to their maximum; this can be done by attempting to empty them with the outlet corked. A dropped or damaged syringe should be considered out of calibration until it is checked.

With regard to time, assessing mechanical recorder time scale accuracy with a stopwatch must be performed at least quarterly. An accuracy of within 2% must be achieved.

Quality Control for Volume-Measuring Devices

The volume accuracy of the spirometer must be checked at least daily, with a single discharge of a 3-L calibrated syringe. Daily calibration checking is highly recommended so that the onset of a problem can be determined within 1 day and also to help define day-to-day laboratory variability. More frequent checks may be required in special circumstances, such as: 1) during industrial surveys or other studies in which a large number of subject maneuvers are carried out, the equipment’s calibration should be checked more frequently than daily; and

2) when the ambient temperature is changing (eg, field studies), volume accuracy must be checked more frequently than daily and the BTPS correction factor appropriately updated.

The accuracy of the syringe volume must be considered in determining whether the measured volume is within acceptable limits. For example, if the syringe has an accuracy of 0.5%, a reading of $\pm 3.5\%$ is appropriate.

The calibration syringe should be stored and used in such a way as to maintain the same temperature and humidity of the testing site. This is best accomplished by keeping the syringe in close proximity to the spirometer, but out of direct sunlight and away from heat sources.

Volume-type spirometer systems must be evaluated for leaks every day. The importance of undertaking this daily test cannot be overstressed. Leaks can be detected by applying a constant positive pressure of ≥ 3.0 cmH₂O (0.3 kPa) with the spirometer outlet occluded (preferably at or including the mouthpiece). Any observed volume loss of .30 mL after 1 minute indicates a leak and needs to be corrected.

At least quarterly, volume spirometers must have their calibration checked over their entire volume range using a calibrated syringe or an equivalent volume standard. The measured volume should be within $\pm 3.5\%$ of the reading or 65 mL, whichever is greater. This limit includes the 0.5% accuracy limit for a 3-L syringe. The linearity check procedure provided by the manufacturer can be used if it is equivalent to 1 of the following procedures: 1) consecutive injections of 1-L volume increments while comparing observed volume with the corresponding cumulative measured volume, eg, 0–1, 1–2, 2–3, ... 6–7 and 7–8 L, for an 8-L spirometer; and 2) injection of a 3-L volume starting at a minimal spirometer volume, then repeating this with a 1-L increment in the start position, eg, 0–3, 1–4, 2–5, 3–6, 4–7 and 5–8 L, for an 8-L spirometer. The linearity check is considered acceptable if the spirometer meets the volume accuracy requirements for all volumes tested.

Quality Control for Flow-Measuring Devices

With regards to volume accuracy, calibration checks must be undertaken at least daily, using a 3-L syringe discharged at least 3 times to give a range of flows varying between 0.5 and 12 L·s⁻¹ (with 3-L injection times of 6 s and 0.5 s). The volume at each flow should meet the accuracy requirement of $\pm 3.5\%$. For devices using disposable flow sensors, a new sensor from the supply used for patient tests should be tested each day.

For linearity, a volume calibration check should be performed weekly with a 3-L syringe to deliver 3 relatively constant flows at a low flow, then 3 at a mid-range flow, and finally 3 at a high flow. The volumes achieved at each of these flows should each meet the accuracy requirement of $\pm 3.5\%$.

Equipment

For measurements of VC and IC, the spirometer or flow meter must comply with the requirements for FVC (as described previously) and be capable of accumulating volume for

≥30 s. Expiratory maneuvers or, ideally, both inspiratory and expiratory maneuvers should be included in the display of VC maneuver. Regardless of whether the inspiratory or expiratory maneuver is used for deriving measurements, a display of the entire recorded VC maneuver must be provided. The maximal expiratory volume must be assessed to determine whether the subject has obtained a plateau in the expiratory effort. For display of the slow VC, the time scale may be reduced to 5 mm·s⁻¹.

Technical Considerations

Minimal recommendations for spirometry systems

Accurate results require accurate equipment. Spirometer equipment recommendations apply to all spirometers and are minimal requirements. In some circumstances, it may be appropriate to exceed these requirements (ie., in some research/surveillance applications). Instrumentation recommendations should be followed to provide accurate spirometric data and information that is comparable from laboratory to laboratory and from 1 time period to another. The accuracy of a spirometry system depends on characteristics of the entire system, from the volume or flow transducer and the use of an in-line filter, to the recorder, display or processor. Changes in any aspect of the equipment or errors at any step in the process can affect the accuracy of the results. For example, if the BTPS correction factor is wrong, an accurately measured FVC will be incorrectly reported. Spirometers are not required to measure all of the indices in [Table A1-3](#), but must meet the recommendations for those that are measured. Accuracy and repeatability recommendations apply over the entire volume range of the instrument.

Table A1-3. Range and Accuracy Recommendations Specified for Forced Expiratory Maneuvers

Test	Range/Accuracy (BTPS)	Flow Range (L·s ⁻¹)	Time (s)	Resistance and Back Pressure	Test Signal
VC	0.5–8 L, ± 3% of reading or ± 0.050 L, whichever is greater	0-14	30		3-L Calibration syringe
FVC	0.5–8 L, ± 3% of reading or ± 0.050 L, whichever is greater	0-14	15	<1.5 cm H ₂ O L ⁻¹ s ⁻¹ (0.15 kPa L ⁻¹ s ⁻¹)	24 ATS waveforms, 3-L Cal Syringe
FEV ₁	0.5–8 L, ± 3% of reading or ± 0.050 L, whichever is greater	0-14	1	<1.5 cm H ₂ O L ⁻¹ s ⁻¹ (0.15 kPa L ⁻¹ s ⁻¹)	24 ATS waveforms
Time	The timepoint from which			Back extrapolation	

Table A1-3. Range and Accuracy Recommendations Specified for Forced Expiratory Maneuvers

Test	Range/Accuracy (BTPS)	Flow Range (L·s ⁻¹)	Time (s)	Resistance and Back Pressure	Test Signal
Zero	all FEV _t measurements are taken.				

FEV_t: forced expiratory volume in t seconds

Body temperature, ambient pressure, saturated with water vapor correction

All spirometry values should be reported at BTPS by any method (measuring temperature and barometric pressure) proven effective by the manufacturer. For volume-type spirometers, the temperature inside the spirometer should be measured for each breathing maneuver. Regardless of the BTPS correction technique used, the ambient temperature must always be recorded with an accuracy of $\pm 1^{\circ}\text{C}$. In situations where the ambient air temperature is changing rapidly ($>3^{\circ}\text{C}$ in <30 min), continuous temperature corrections may be necessary. Spirometer users should be aware of potential problems with testing performed at lower ambient temperatures: 17°C is the lower limit for ambient temperature, unless a manufacturer states that their spirometer will operate accurately at lower ambient temperatures. If barometric pressure is not used in calculating the BTPS correction factor, the range of barometric pressures over which the BTPS correction factor is valid must be published.

Appendix C Additional Safety Information

Additional Safety Information

Further Guidance on the Definition of a Serious Adverse Event (SAE)

Life threatening

‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it occurred or it is suspected that use or continued use of the product would result in the subject’s death. ‘Life-threatening’ does not mean that had an AE occurred in a more severe form it might have caused death (eg, hepatitis that resolved without hepatic failure).

Hospitalization

Outsubject treatment in an emergency room is not in itself a serious AE, although the reasons for it may be (eg, bronchospasm, laryngeal edema). Hospital admissions and/or surgical operations planned before or during a study are not considered AEs if the illness or disease existed before the subject was enrolled in the study, provided that it did not deteriorate in an unexpected way during the study.

Important medical event or medical intervention

Medical and scientific judgement should be exercised in deciding whether a case is serious in situations where important medical events may not be immediately life threatening or result in death, hospitalization, disability or incapacity but may jeopardize the subject or may require medical intervention to prevent one or more outcomes listed in the definition of serious. These should usually be considered as serious.

Simply stopping the suspect drug does not mean that it is an important medical event; medical judgement must be used.

- Angioedema not severe enough to require intubation but requiring iv hydrocortisone treatment
- Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment with N-acetylcysteine
- Intensive treatment in an emergency room or at home for allergic bronchospasm
- Blood dyscrasias (eg, neutropenia or anemia requiring blood transfusion, etc.) or convulsions that do not result in hospitalization

Development of drug dependency or drug abuse

A Guide to Interpreting the Causality Question

When making an assessment of causality consider the following factors when deciding if there is a ‘reasonable possibility’ that an AE may have been caused by the drug.

- Time Course. Exposure to suspect drug. Has the subject actually received the suspect drug? Did the AE occur in a reasonable temporal relationship to the administration of the suspect drug?
- Consistency with known drug profile. Was the AE consistent with the previous knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same pharmacological class? Or could the AE be anticipated from its pharmacological properties?
- De-challenge experience. Did the AE resolve or improve on stopping or reducing the dose of the suspect drug?
- No alternative cause. The AE cannot be reasonably explained by another etiology such as the underlying disease, other drugs, other host or environmental factors.
- Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced after having been stopped? AstraZeneca would not normally recommend or support a re-challenge.
- Laboratory tests. A specific laboratory investigation (if performed) has confirmed the relationship.

In difficult cases, other factors could be considered such as:

- Is this a recognized feature of overdose of the drug?
- Is there a known mechanism?

Causality of ‘related’ is made if following a review of the relevant data, there is evidence for a ‘reasonable possibility’ of a causal relationship for the individual case. The expression ‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are facts (evidence) or arguments to suggest a causal relationship.

The causality assessment is performed based on the available data including enough information to make an informed judgment. With limited or insufficient information in the case, it is likely that the event(s) will be assessed as ‘not related’.

Causal relationship in cases where the disease under study has deteriorated due to lack of effect should be classified as no reasonable possibility.

Appendix D Instructions for Use of Inhaled Medications

Instructions for Use of Inhaled Medications

Instructions for Use of the AS MDI and Placebo for AS MDI

1. How do I store the inhaler?

- The inhaler should be stored between 20°C-25°C (68°-77°F) as directed by the label.

2. Preparation of the Inhaler

- Take the inhaler out of the pouch. Safely throw away the pouch and the desiccant packet that comes inside the pouch.
- Take the cap off the inhaler by gently squeezing the sides of the dust-cap and pulling off.
- Inspect the front of the inhaler and make sure there is nothing inside the mouthpiece of the inhaler. Make sure the canister is fully and firmly inserted into the actuator.
- The inhaler must be primed before first use. Priming involves releasing a certain number of sprays (4) into the air before first use of the inhaler. Shaking and priming the inhaler fills a chamber inside the canister with the correct dose and mix of medication so that the inhaler is ready to use.
- To prime the inhaler, gently shake the inhaler for 5-10 seconds and then spray once into the air away from yourself and others.
NOTE: an audible “click” may be heard which is advancement of the dose counter and considered normal.
- Wait approximately 5-10 seconds and then repeat step #2.2.5, three more times.

3. Using the inhaler

- The inhaler should be held upright with the mouthpiece at the bottom and the canister at the top as pictured in Figure 1.
- Shake the inhaler for 5 to 10 seconds.
- Breathe out fully through your mouth, expelling as much air from your lungs as possible. Tilt your head back slightly, place the mouthpiece into your mouth, holding the inhaler with the mouthpiece down, and closing

your lips around it. To allow the medication to enter your lungs, keep your tongue flat on the bottom of your mouth.

- While breathing in deeply and slowly through your mouth, fully depress the top of the dose counter with your index finger. Immediately after the spray is delivered, release your finger from the canister. When you have breathed in fully, remove the inhaler from your mouth and close your mouth.
- Hold your breath as long as possible, up to 10 seconds, and then breathe normally.
- If more than one spray is necessary, repeat steps 2.3.2 to 2.3.5 the necessary number of times.
- If the device will be used again, place the dust-cap back onto the device.

Figure 1. Metered Dose Inhaler Diagram



Instructions for Use of the PROVENTIL HFA

Attention Health Care Professional:

Detach Patient's Instructions for Use from package insert and dispense with the product PROVENTIL® HFA

(albuterol sulfate)

Inhalation Aerosol

FOR ORAL INHALATION ONLY

Patient's Instructions for Use




Figure 1




Figure 2

Before using your PROVENTIL® HFA (albuterol sulfate) Inhalation Aerosol, read complete instructions carefully. Children should use PROVENTIL HFA Inhalation Aerosol under adult supervision, as instructed by the patient's doctor

Please note that indicates that this inhalation aerosol does not contain chlorofluorocarbons (CFCs) as the propellant.

1. **SHAKE THE INHALER WELL** immediately before each use. **Then remove the cap from the mouthpiece** (see Figure 1). **Check mouthpiece for foreign objects prior to use.** Make sure the canister is fully inserted into the actuator.

2. As with all aerosol medications, it is recommended to prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than 2 weeks. Prime by releasing four “test sprays” into the air, away from your face.
3. BREATHE OUT FULLY THROUGH THE MOUTH, expelling as much air from your lungs as possible. Place the mouthpiece fully into the mouth, holding the inhaler in its upright position (see Figure 2) and closing the lips around it.
4. WHILE BREATHING IN DEEPLY AND SLOWLY THROUGH THE MOUTH, FULLY DEPRESS THE TOP OF THE METAL CANISTER with your index finger (see Figure 2).
5. HOLD YOUR BREATH AS LONG AS POSSIBLE, up to 10 seconds. Before breathing out, remove the inhaler from your mouth and release your finger from the canister.
6. If your physician has prescribed additional puffs, wait 1 minute, shake the inhaler again, and repeat steps 3 through 5. Replace the cap after use.
7. KEEPING THE PLASTIC MOUTHPIECE CLEAN IS EXTREMELY IMPORTANT TO PREVENT MEDICATION BUILDUP AND BLOCKAGE. THE MOUTHPIECE SHOULD BE WASHED, SHAKEN TO REMOVE EXCESS WATER, AND AIR DRIED THOROUGHLY AT LEAST ONCE A WEEK. INHALER MAY STOP SPRAYING IF NOT PROPERLY CLEANED. **Routine cleaning instructions:** Step 1. To clean, remove the canister and mouthpiece cap. Wash the mouthpiece through the top and bottom with warm running water for 30 seconds at least once a week (see Figure A). **Never immerse the metal canister in water.**




Figure A

Wash mouthpiece under warm running water.




Figure B

Allow mouthpiece to air dry, such as overnight.




Figure C

When blocked, little or no medicine comes out. Step 2. To dry, shake off excess water and let the mouthpiece air dry thoroughly, such as overnight (see Figure B). When the mouthpiece is dry, replace the canister and the mouthpiece cap. Blockage from medication buildup is more likely to occur if the mouthpiece is not allowed to air dry thoroughly. **IF YOUR INHALER HAS BECOME BLOCKED** (little or no medication coming out of the mouthpiece, see Figure C), wash the mouthpiece as described in Step 1 and air dry thoroughly as described in Step 2. **IF YOU NEED TO USE YOUR INHALER BEFORE IT IS COMPLETELY DRY, SHAKE OFF EXCESS WATER**, replace the canister, and test spray twice into the air, away from your face, to remove most of the water remaining in the mouthpiece. Then take your dose as prescribed. **After such use, rewash and air dry thoroughly as described in Steps 1 and 2.**

8. The correct amount of medication in each inhalation cannot be assured after 200 actuations, even though the canister is not completely empty. The canister should be

discarded when the labeled number of actuations have been used. Before you reach the specific number of actuations, you should consult your physician to determine whether a refill is needed. Just as you should not take extra doses without consulting your physician, you also should not stop using PROVENTIL HFA Inhalation Aerosol without consulting your physician.

You may notice a slightly different taste or spray force than you are used to with PROVENTIL HFA Inhalation Aerosol, compared to other albuterol inhalation aerosol products.

DOSAGE:

Use only as directed by your physician.

WARNINGS:

The action of PROVENTIL® HFA Inhalation Aerosol should last up to 4 to 6 hours. PROVENTIL HFA Inhalation Aerosol should not be used more frequently than recommended. Do not increase the number of puffs or frequency of doses of PROVENTIL HFA Inhalation Aerosol without consulting your physician. If you find that treatment with PROVENTIL HFA Inhalation Aerosol becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, medical attention should be sought immediately. While you are taking PROVENTIL HFA Inhalation Aerosol, other inhaled drugs should be taken only as directed by your physician. If you are pregnant or nursing, contact your physician about the use of PROVENTIL HFA Inhalation Aerosol.

Common adverse effects of treatment with PROVENTIL HFA Inhalation Aerosol include palpitations, chest pain, rapid heart rate, tremor, or nervousness. Effective and safe use of PROVENTIL HFA Inhalation Aerosol includes an understanding of the way that it should be administered. Use PROVENTIL HFA Inhalation Aerosol only with the yellow actuator supplied with the product. The PROVENTIL HFA Inhalation Aerosol actuator should not be used with other aerosol medications.

For best results, use at room temperature. Avoid exposing product to extreme heat and cold.

Shake well before use.

Contents Under Pressure.

Do not puncture. Do not store near heat or open flame. Exposure to temperatures above 120°F may cause bursting. Never throw container into fire or incinerator. Store between 15° - 25°C (59° - 77°F). **Store the inhaler with the mouthpiece down.** Avoid spraying in eyes. Keep out of reach of children.

Further Information: Your PROVENTIL® HFA (albuterol sulfate) Inhalation Aerosol does not contain chlorofluorocarbons (CFCs) as the propellant. Instead, the inhaler contains a hydrofluoroalkane (HFA-134a) as the propellant.

Developed and Manufactured by: 3M Health Care Limited

Loughborough UK or 3M Drug Delivery **653300**
Systems Northridge, CA 91324, USA Rev.

12/14 Copyright © 1996, 2011, 2012 Merck

Sharp & Dohme Corp., a subsidiary of

Merck & Co., Inc.

All rights reserved.

Instructions for Use of the VENTOLIN HFA

This Patient Information leaflet summarizes the most important information about VENTOLIN HFA. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your healthcare provider or pharmacist for information about VENTOLIN HFA that was written for healthcare professionals.

For more information about VENTOLIN HFA, call 1-888-825-5249 or visit our website at www.ventolin.com.

What are the ingredients in VENTOLIN HFA?

Active ingredient: albuterol sulfate

Inactive ingredient: propellant HFA-134a

Instructions for Use

For Oral Inhalation Only

Your VENTOLIN HFA inhaler




Figure A




Figure B

- The metal canister holds the medicine. **See Figure A.**
- The canister has a counter to show how many sprays of medicine you have left. The number shows through a window in the back of the actuator. **See Figure B.**
- The counter starts at either **204** or **064**, depending on which size inhaler you have. The number will count down by 1 each time you spray the inhaler. The counter will stop counting at **000**.
- **Do not try to change the numbers or take the counter off the metal canister.** The counter cannot be reset, and it is permanently attached to the canister.
- The blue plastic actuator sprays the medicine from the canister. The actuator has a protective cap that covers the mouthpiece. **See Figure A.** Keep the protective cap on the mouthpiece when the canister is not in use. The strap keeps the cap attached to the actuator.

- **Do not** use the actuator with a canister of medicine from any other inhaler.
- **Do not** use a VENTOLIN HFA canister with an actuator from any other inhaler.

Before using your VENTOLIN HFA inhaler

- Take VENTOLIN HFA out of the foil pouch just before you use it for the first time. Safely throw away the pouch and the drying packet that comes inside the pouch.
- The inhaler should be at room temperature before you use it.
- If your child needs to use VENTOLIN HFA, watch your child closely to make sure your child uses the inhaler correctly. Your healthcare provider will show you how your child should use VENTOLIN HFA.

Priming your VENTOLIN HFA inhaler




Figure C




Figure D

- **Before you use VENTOLIN HFA for the first time, you must prime the inhaler so that you will get the right amount of medicine when you use it.**
- To prime the inhaler, take the cap off the mouthpiece and shake the inhaler well. Then spray the inhaler 1 time into the air away from your face. **See Figure C. Avoid spraying in eyes.**
- Shake and spray the inhaler like this 3 more times to finish priming it. The counter should now read **200** or **060**, depending on which size inhaler you have. **See Figure D.**
- You must prime your inhaler again if you have not used it in more than 14 days or if you drop it. Take the cap off the mouthpiece and shake and spray the inhaler 4 times into the air away from your face.

How to use your VENTOLIN HFA inhaler

Follow these steps every time you use VENTOLIN HFA.




Figure E




Figure F

Step 1. Make sure the canister fits firmly in the actuator. The counter should show through the window in the actuator.

Shake the inhaler well before each spray.

Take the cap off the mouthpiece of the actuator. Look inside the mouthpiece for foreign objects, and take out any you see.

Step 2. Hold the inhaler with the mouthpiece down. **See Figure E.**

Step 3. Breathe out through your mouth and push as much air from your lungs as you can. Put the mouthpiece in your mouth and close your lips around it. **See Figure F.**

Step 4. Push the top of the canister **all the way down** while you breathe in deeply and slowly through your mouth. **See Figure F.**

Step 5. After the spray comes out, take your finger off the canister. After you have breathed in all the way, take the inhaler out of your mouth and close your mouth.

Step 6. **Hold your breath for about 10 seconds**, or for as long as is comfortable. **Breathe out slowly as long as you can.**

If your healthcare provider has told you to use more sprays, wait 1 minute and shake the inhaler again. Repeat Steps 2 through Step 6.

Step 7. Put the cap back on the mouthpiece after every time you use the inhaler. Make sure it snaps firmly into place.

Cleaning your VENTOLIN HFA inhaler

If you need to use your inhaler before the actuator is completely dry:

- Shake as much water off the actuator as you can.
- Put the cap on the mouthpiece and then put the canister in the actuator and make sure it fits firmly.
- Shake the inhaler well and spray it 1 time into the air away from your face.
- Take your VENTOLIN HFA dose as prescribed.
- Follow cleaning Steps 8 through 13 above.

Replacing your VENTOLIN HFA inhaler

- **When the counter reads 020**, you should refill your prescription or ask your healthcare provider if you need another prescription for VENTOLIN HFA.
- **Throw the inhaler away** when the counter reads **000** or 12 months after you opened the foil pouch, whichever comes first. You should not keep using the inhaler when the counter reads **000** because you will not receive the right amount of medicine.
- **Do not use the inhaler** after the expiration date, which is on the packaging it comes in.

For correct use of your VENTOLIN HFA inhaler, remember:

- The canister should always fit firmly in the actuator.
- Breathe in deeply and slowly to make sure you get all the medicine.
- Hold your breath for about 10 seconds after breathing in the medicine. Then breathe out fully.
- Always keep the protective cap on the mouthpiece when your inhaler is not in use.
- Always store your inhaler with the mouthpiece pointing down.
- Clean your inhaler at least 1 time each week.

If you have questions about VENTOLIN HFA or how to use your inhaler, call GlaxoSmithKline (GSK) at 1-888-825-5249 or visit www.ventolin.com.

This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.

Instructions for Use of the ATROVENT HFA

How to Use the ATROVENT HFA Inhaler

This quick overview can help you understand how to use your ATROVENT HFA inhaler. For complete information on using ATROVENT HFA, please see the Instructions for Use that come with your prescription.



For complete information on using ATROVENT HFA, please see the Instructions for Use that come with your prescription.

Using ATROVENT HFA requires 5 main steps:

1. Insert the metal canister into the clear end of the mouthpiece (see Figure 1).

- Make sure the canister is fully and firmly inserted into the mouthpiece

2. Remove the green protective dust cap.

- If the cap is not on the mouthpiece, make sure there is nothing in the mouthpiece before use
- ATROVENT HFA should be "primed" before you use the first dose by pushing the canister against the mouthpiece, and spraying the medicine twice into the air. Do not spray the medicine into your eyes




Figure 1

3. Breathe out (exhale) deeply through your mouth.

- Hold the inhaler upright (see Figure 2), between your thumb and first 2 fingers. Put the mouthpiece in your mouth and close your lips. Keep your eyes closed so that no medicine will be sprayed into your eyes




Figure 2

4. Breathe in (inhale) slowly through your mouth and at the same time spray the ATROVENT HFA into your mouth.

- To spray ATROVENT HFA, firmly press the canister against the mouthpiece 1 time. Keep breathing in deeply

5. Hold your breath for 10 seconds and then take the mouthpiece out of your mouth and breathe out slowly. Wait at least 15 seconds and repeat steps 3 and 4.

IMPORTANT SAFETY INFORMATION

Do not use ATROVENT HFA if you are allergic to ipratropium or any of the ingredients in ATROVENT HFA or to atropine or similar drugs.

Please see additional Important Safety Information on the next page and full [Prescribing Information](#), including Instructions for Use.

ATROVENT® HFA
(ipratropium bromide HFA)
INHALATION AEROSOL

IMPORTANT SAFETY INFORMATION (cont'd)

ATROVENT HFA is not a rescue medicine and should not be used for treating sudden breathing problems. Your doctor may give you other medicine to use for sudden breathing problems.

Allergic reactions may occur, including itching, swelling of the face, lips, tongue, or throat (involving difficulty in breathing or swallowing), rash, hives, bronchospasm (airway narrowing), or anaphylaxis. Some of these may be serious. If you experience any of these symptoms, stop taking ATROVENT HFA at once and call your doctor or get emergency help.

ATROVENT HFA can cause the narrowing of the airways to get worse (paradoxical bronchospasm) which may be life threatening. If this happens, stop taking ATROVENT HFA at once and call your doctor or get emergency help.

ATROVENT HFA may increase eye pressure which may cause or worsen some types of glaucoma.

Do not get the spray into your eyes. The spray may cause eye pain or discomfort, blurred vision, enlarged pupils, seeing halos or colored images along with red eyes. If you have any of these symptoms, stop taking Atrovent HFA and call your doctor right away.

Dizziness and blurred vision may occur with ATROVENT HFA. Should you experience these symptoms, use caution when engaging in activities such as driving a car or operating appliances or machinery.

ATROVENT HFA may cause difficulty with urination. Symptoms may include difficulty passing urine and/or painful urination. If you have any of these symptoms, stop taking ATROVENT HFA and call your doctor right away.

The most common side effects reported with use of ATROVENT HFA were bronchitis, COPD flare-up (exacerbation), shortness of breath and headache.

Tell your doctor about all medicines you are taking, including eye drops. Ask your doctor if you are taking any anticholinergic medicines because taking them together with ATROVENT HFA can increase side effects.

INDICATION FOR USE

ATROVENT HFA (ipratropium bromide HFA) Inhalation Aerosol is a prescription maintenance treatment for bronchospasm (airway narrowing) in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information on the previous page and full [Prescribing Information](#), including Instructions for Use.

ATROVENT[®] HFA
(ipratropium bromide HFA)
INHALATION AEROSOL

Instructions for Use of PULMICORT FLEXHALER


How to Get Started Using Your PULMICORT FLEXHALER® (budesonide inhalation powder, 90 mcg & 180 mcg)

Please read these instructions carefully before you start to take your medicine, and use only as directed by a health care professional.

Priming Your PULMICORT FLEXHALER

Before you use a new PULMICORT FLEXHALER for the first time, you must prime it.

Figure 1- Parts of your PULMICORT FLEXHALER



To prime your PULMICORT FLEXHALER follow the steps below:

1. Hold the inhaler by the brown grip so that the white cover points upward (upright position). With the other hand, turn the white cover and lift off (see Figure 2).
2. Continue to hold your PULMICORT FLEXHALER upright as shown in Figure 1. Use your other hand to hold the inhaler in the middle. Do not hold the inhaler at the top of the mouthpiece.
3. Twist the brown grip as far as it will go in one direction and then fully back again in the other direction until it stops (it does not matter which way you turn it first). You will hear a "click" during one of the twisting movements (see Figure 3 and 4).
4. Repeat Step 3. Your PULMICORT FLEXHALER is now primed. You are ready to load your first dose.

You do not have to prime your PULMICORT FLEXHALER again after this even if you do not use it for a period of time.



Figure 2 - Load



Figure 3 - Twist



Figure 4 - Click



Figure 5 - Inhale

Loading a Dose

1. Hold your PULMICORT FLEXHALER upright as described above. With your other hand, twist the white cover and lift it off (see Figure 2).
2. Continue to hold your PULMICORT FLEXHALER upright to be sure that the right dose of medicine is loaded.
3. Use your other hand to hold the inhaler in the middle. Do not hold the mouthpiece when you load the inhaler.
4. Twist the brown grip fully in one direction as far as it will go. Twist it fully back again in the other direction as far as it will go (it does not matter which way you turn it first) [see Figure 3].
 - You will hear a "click" during one of the twisting movements (see Figure 4)
 - PULMICORT FLEXHALER will only give one dose at a time, no matter how often you click the brown grip, but the dose indicator will continue to move (advance). This means that if you continue to move the brown grip, it is possible for the indicator to show fewer doses or zero doses even if more doses are left in the inhaler
 - Do not shake the inhaler after loading it

Inhaling a Dose

1. Turn your head away from the inhaler and breathe out (exhale). If you accidentally blow into your inhaler after loading a dose, follow the instructions for loading a new dose.
2. Place the mouthpiece in your mouth and close your lips around the mouthpiece. Breathe in (inhale) deeply and forcefully through the inhaler (see Figure 5).
3. You may not sense the presence of any medication entering your lungs when inhaling from PULMICORT FLEXHALER. This lack of sensation does not mean that you did not get the medication. You should not repeat your inhalations even if you did not feel the medication when inhaling.
4. Do not chew or bite on the mouthpiece.
5. Remove the inhaler from your mouth and exhale. **Do not blow or exhale into the mouthpiece.**
6. If more than one dose is prescribed repeat the steps above.
7. When you are finished taking your dose, place the white cover back on the inhaler and twist shut.
8. **Rinse your mouth with water after each dose to decrease your risk of getting thrush. Do not swallow the water.**

**Pulmicort
Flexhaler®**

(budesonide inhalation powder,
90 mcg & 180 mcg)

Reading the Dose Indicator Window

- The label on the box or cover will tell you how many doses are in your PULMICORT FLEXHALER
- Your PULMICORT FLEXHALER has a dose indicator window just below the mouthpiece. The dose indicator tells you about how many doses are left in the inhaler. Look at the middle of the window to find out about how many doses are left in your inhaler ([see Figure 6](#))
- The dose indicator is connected to the turning grip and moves (counts down) every time a dose is loaded. **It is not likely that you will see the dose indicator move with each dose.** You can usually see the indicator move each time you use about 5 doses
- The dose indicator starts with either the number 60 or 120 when full, depending upon the strength of the inhaler. The indicator is marked in intervals of 10 doses. Markings are either with numbers or dashes (alternating), counting down to "0"

60-Dose Inhaler	120-Dose Inhaler	Dose indicator starts at 60 or 120 depending on strength (90 mcg or 180 mcg) of the inhaler and counts down to 0.
20	80	
40	100	
60	120	




Figure 6 - Dose Indicator




Figure 7 - Empty

- The dose indicator will tell you about how many doses are left in your PULMICORT FLEXHALER
- If you complete the instructions for loading the dose more than one time before you inhale the dose, you will only receive one dose. The dose indicator will move a small amount but it is not likely that you will see the dose indicator move with each dose
- Your inhaler is empty when the number 0 on the red background reaches the middle of the dose indicator window. Throw away this inhaler. The inhaler may not give you the right amount of medicine, even though it may not feel completely empty and may seem like it continues to work ([see Figure 7](#))
- Do not put your PULMICORT FLEXHALER in water (do not immerse it) to find out if it is empty. Check the dose indicator window to see how many doses are left
- Refill your PULMICORT FLEXHALER prescription before your medicine runs out. You will get a new inhaler each time you refill your prescription

Cleaning your PULMICORT FLEXHALER

- Keep your PULMICORT FLEXHALER clean and dry at all times. Do not immerse it in water
- Wipe the outside of the mouthpiece one time each week with a dry tissue
- Do not use water or liquids when cleaning the mouthpiece
- Do not try to remove the mouthpiece or twist it

Do not use your PULMICORT FLEXHALER if it has been damaged or if the mouthpiece has become detached. Talk to your doctor or pharmacist if you have any problems with your PULMICORT FLEXHALER.

IMPORTANT INFORMATION ABOUT PULMICORT FLEXHALER

Important Safety Information

PULMICORT FLEXHALER is not a bronchodilator and should NOT be used to treat an acute asthma attack. If you are switching to PULMICORT FLEXHALER from an oral corticosteroid, follow your doctor's instructions to avoid serious health risks when you stop using oral corticosteroids.

Avoid exposure to infections such as chicken pox and measles. Tell your doctor immediately if exposed. Inhaled corticosteroids may cause a reduction in growth rate. The long-term effect on final adult height is unknown.

Rare instances of glaucoma, increased intraocular pressure, cataracts have been reported following the inhaled administration of corticosteroids.

Please see last page for continued Important Safety Information on PULMICORT FLEXHALER

**Pulmicort
Flexhaler®**
(budesonide inhalation powder,
90 mcg & 180 mcg)

Appendix E Sponsor Signatory

Sponsor Signatory

Study Title:	Albuterol Sulfate Pressurized Inhalation Suspension (PT007) Cumulative Dose Study in Subjects With Mild to Moderate Asthma
Study Number:	D6930C00002 (PT007002)
Final Date:	15 March 2018



Appendix F Investigator's Agreement and Signature Page

Investigator's Agreement and Signature Page

Study Title: Albuterol Sulfate Pressurized Inhalation Suspension (PT007)
Cumulative Dose Study in Subjects With Mild to Moderate
Asthma

Study Number: D6930C00002 (PT007002)

Final Date: 15 March 2018

I agree:

To assume responsibility for the proper conduct of the study at this site.

To conduct the study in compliance with the protocol and with any other study conduct procedures provided by Pearl Therapeutics, Inc. (hereafter referred to as Pearl).

Not to implement any changes to the protocol without agreement from the Sponsor and prior review and written approval from the IRB/IEC, except where necessary to eliminate an immediate hazard to the subjects, or for administrative aspects of the study (where permitted by all applicable regulatory requirements).

That I am aware of, and will fully comply with GCP and all applicable regulatory requirements.

That I am thoroughly familiar with the appropriate use of the investigational product(s), and other information provided by the Sponsor including, but not limited to, the following: the protocol and the current Investigator Brochure (IB).

To ensure that all persons assisting me with the study are qualified, adequately informed about the investigational product(s) and of their study-related duties and functions.

To supply Pearl with any necessary information regarding ownership interest and financial ties; to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study; and agree that Pearl may disclose any information it has about such ownership interests and financial ties to regulatory authorities.

I agree to report all information or data in accordance with the protocol and any other study conduct procedures provided by Pearl.

That since the information in this protocol and IB is confidential, I understand that its disclosure to any third parties, other than those involved in approval, supervision or conduct of the study is prohibited.

To accurately transfer all required data from each subject's source document to the eCRFs. The eCRFs will be provided to the Sponsor in a timely manner at the completion of the study, or as otherwise specified by the Sponsor. To allow authorized representatives of Pearl or regulatory authority representatives to conduct on-site visits to review, audit and copy study documents. I will personally meet with these representatives to answer any study-related questions.

Signature: _____ Date: _____

Name: _____

Site Name: _____